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Yeasts such as Saccharomyces cerevisiae and Pichia pastoris, are challenging the dominance 
of Escherichia coli as the preferred unicellular system for the manufacture of 
biopharmaceuticals, primarily because of their ability to produce and secrete complex 
proteins containing disulphide bonds. The most significant bottleneck in the secretion of 
recombinant proteins from yeast cells is the relatively low abundance of key processing 
enzymes (such as Sil1 or Lhs1), and chaperones in the secretion pathway yet nevertheless 
laboratory strains of yeasts have been successfully engineered to secrete a wide range of 
complex recombinant proteins. In this project I am asking whether a group of unmodified 
wild strains are efficient at secreting large amounts of recombinant protein. To do this I am 
examining the efficacy of protein secretion in a range of novel wild strains some of which 
have been discovered in remote uninhabited regions around the globe. To achieve this aim, I 
have first characterised the ability of various wild strains to secrete the yeast dsRNA virus-
ĞŶĐŽĚĞĚ  ‘ŬŝůůĞƌ ƚŽǆŝŶ ?  ?<d ? ?   ‘ŚĂůŽ ? ĂƐƐĂǇ ŚĂƐ ďĞĞŶ ƵƐĞĚ ƚŽ ƋƵĂŶƚŝĨǇ ƚŚĞ ĂŵŽƵŶƚ of KT 
secreted by each strain. To this end technology to insert the KT gene into strains lacking 
auxotrophic makers was developed. This analysis has also included characterising the 
secretome of the strains. 8 strains were identified as possible hosts for recombinant protein 
production, with 3 of these strains showing a high level of secretion. A set of industrial used 
 ‘ĚŽŵĞƐƚŝĐĂƚĞĚ ‘ƐƚƌĂŝŶƐǁĞƌĞĂůƐŽƵƐĞĚĂƐĂĐŽŶƚƌŽů ?dŚĞƐĞƐƚƌĂŝŶƐŚĂĚ KT secretion tested as 
well as gaussia luciferase secretion. There was a marked difference between the strains and 
between the two different proteins used, in terms of secretion levels  
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Abbrviations  
µg  Microgram 
µl  Microliter 
A.U. Arbitrary units 
Amp  Ampicillin 
CFU  Colony Forming Units 
CHO cells Chinese hamster ovary cells 
CRISPR  Clustered regularly interspaced short palindromic repeats 
DNA Deoxyribonucleic Acid 
E.coli  Escherichia coli 
ER Endoplasmic reticulum 
Et al  Et alia 
EtBr  Ethidium Bromide 
g  Gram 
H2O  Water 
hrs hours 
IBs Inclusion bodies 
kDa  KiloDalton 
KT Killer toxin 
Leu  Leucine 
LiAc  Lithium Acetate 
mins minutes 
ml  Millilitre 
mm milimeter 
O.D600  Optical Density at a 600 nanometre wavelength 
P. pastoris  Pichia pastoris 
PCR  Polymerase Chain Reaction 
PEG  Polyethylene Glycol 
PTM Post-translational modification 
RNA Ribonucleic Acid 
ROS Reactive oxygen species 
Rpm  Revolutions per minute 
S.cerevisiae  Saccharomyces cerevisiae 
SD  Synthetic Defined 
SDS PAGE  Sodium Dodecyl Sulfate Polyacrylamide 
sgRNA Single guide RNA 
TEMED  Tetramethylethylenediamine 
tRNA  transfer RNA 
Ura  Uracil 
V  Volt 
w/v  Weight per volume 
wt Wild type 
YEPD  Yeast Extract Peptone Dextrose 
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1. Introduction 
The harnessing of single-celled organisms to produce recombinant proteins revolutionised 
the production of proteins, both in an industrial and research setting, and has led to hugely 
more efficient production methods. Whereas before many tons of bio matter were required 
to purify very small amounts of proteins such as insulin, the use of single-celled organisms as 
recombinant protein expression hosts has allowed less expensive and rapid production of a 
wide variety of useful biopharmaceuticals, enzymes and other useful bio-products. In the 
following, I review the improvements made over the last few decades that have increased 
the efficiency of secretion of recombinant proteins when using yeasts as host organisms. I 
also look at both E. coli and Chinese hamster ovary cells as host for recombinant protein 
expression. 
1.1 Recombinant protein expression systems 
Escherichia coli was the first microbial species to be used for recombinant protein 
production and still remains the preferred cellular host with 50% of all commercial proteins 
being produced In E. coli1 . The reasons for its dominant position are as a recombinant host 
system; that it is easy to culture and has been optimised in different ways to inexpensively 
produce useful products2,3. This is achieved whilst having a very high protein yield in 
comparison to eukaryotic systems4. However there are highly notable downsides to using an 
E. coli host system, some of which are explored below.  
1.1.1 Uncommon codon interference in recombinant protein production in Escherichia coli 
There are 61 mRNA codons possible with the genetic code, however these codons are not all 
represented evenly in the genome of a given organism. In fact different organisms display 
different biases5, and as a result, the levels of tRNA available to a cell reflect its codon bias. 
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The tRNA levels in Escherichia coli are no exception and reflect the levels of use of 
endogenous codon usage6 to optimise the decoding speed of endogenous proteins. 
However, many recombinant proteins are modified proteins originating in eukaryotes (e.g. 
monoclonal anti-bodies) which have a different set of codon biases. These different biases 
leads to a drop in efficiency of decoding, frameshifts, swapping of similar amino acids (e.g. 
lysine for arginine), or even stalling or premature terminator of translation, leading to a 
truncated protein7.  
Current approaches to this problem include codon optimisation; the process of altering the 
codons in a given gene, to better complement the native tRNA levels in the host system8,9,10. 
Whilst codon optimisation has shown an increase protein production speed in E. coli9, it is a 
costly and time consuming process. Depending on the exact codon makeup of the original 
gene used, large regions may have to be altered for efficient protein expression. Snajder et 
al found that to generate high levels of Pernisine (a protein used in industrial cleaning), 
25.3% of the gene was altered10 to allow efficient production levels. 
Whilst codon optimisation may be required in yeast to expresses proteins that originate in 
bacteria11, the increase in production of mono-clonal anti-bodies, and other  
biopharmaceuticals with their origins in eukaryotes makes this requirement much less 
common than seen in  E.coli systems. 
1.1.2 The inclusion body problem 
Inclusion bodies (IBs) are the result of protein aggregates and have often been observed in 
recombinant E. coli since the beginning of its use as an expression host. IBs are formed of 
aggregated proteins, as a result of unbalance in the aggregation/solubilisation equilibrium. 
This equilibrium is pushed towards the crystallisation of proteins, when large volumes of 
11 | P a g e  
 
non-native proteins are produced, the results of strong promoters or high inducer 
concentrations. This large voůƵŵĞŽĨƉƌŽƚĞŝŶ ĨĂƌŽƵƚƐƚƌŝƉƐ ƚŚĞĐĞůů ?ƐĂďŝůŝƚǇ ƚŽƉƌŽƉĞƌůǇ ĨŽůĚ
them, and so the excess proteins begin to aggregate, and form IBs12. 
IBs act as a large bottle neck to protein secretion, having been observed to occupy up to 20% 
of the total cellular volume at peak protein production13.  Large volumes of active bio 
product can become trapped inside IBs, and are wasted. whilst catalytic activity has been 
observed in IBs and processes have been developed to recover bio-active products from IBs, 
the yields these processes are often low, and the processes themselves are often labour 
intensive14. 
1.1.3 Post-translational modifications in Escherichia coli 
Many recombinant proteins have complex post-translational modifications (PTM); these 
range from N- and O-linked glycosylation, to multiple disulphide bonds. These modifications 
are added by families of enzyme (such as PDI, or NMT-1), and often require co-factors. 
Eukaryotic cell have sets of chaperones, within membrane-bond organelles, which ensure 
the conditions to correctly create these PTMs are generated. For example the formation of 
disulphide bonds, both intra- and inter-protein, requires an oxidising environment, which is 
not found in the cytoplasm of wt E.coli, and proteins must be exported to the periplasm to 
be properly folded. This lack of folding increases the chance of the formation of inclusions 
bodies (see above), especially in disulphide-rich proteins, such as Fab anti-body fragments.  
Many recombinant proteins require glycosylation for proper folding and function.  Non-
glycosylated versions of glycoproteins tend to be misfolded, biologically inactive or quickly 
broken down by the cell15,16. E. coli and other prokaryotes lack much of the machinery 
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required for glycosylation of any kind, and this can present a major issue in recombinant 
protein production17. 
1.2 Chinese hamster ovary cells as protein expression hosts 
Chinese hamster ovary (CHO) cells are often used as an expression host for recombinant 
proteins. Being eukaryotic cells, CHO cells have the ability to produce a large range of PTMs, 
and so can be used to produce a large range of recombinant proteins especially those 
needed by biopharma companies. For example, 3D6 single chain Fv-Fc anti-HIV-118, an anti-
HIV antibody or recombinant human (rh)Thrombin19. As CHO cells are genetically similar to 
humans, containing many of the same chaperones and enzymes, it follows that CHO cells are 
used for some of the more complex biopharmaceuticals. However, whilst the native 
machinery in yeasts is less complex and possible less efficient than in mammalian cells, such 
as CHO, these are not the only factors to consider when looking at overall recombinant 
ƉƌŽƚĞŝŶ ƐĞĐƌĞƚŝŽŶ ? /ƚ ŚĂƐ ďĞĞŶ ƐŚŽǁŶ ƚŚĂƚ  ‘ůĞƐƐ ĐŽŵƉůĞǆ ? ƉƌŽƚĞŝŶƐ ƐƵĐŚ ĂƐ ŚƵŵĂŶ ƐĞƌƵŵ
albumin are secreted in much greater quantities by yeasts than by CHO cells due to several 
factors such as cellular replication time, and maximum cell density20. 
There are also economic factors to consider: CHO cells require more complex media in which 
to grow in. This tends to be very expensive, compared to the inexpensive media used for 
yeasts such as S. cerevisiae or P. pastoris. CHO cell lines are also much more expensive to 
buy than yeasts or bacterial hosts, raising the initial investment required. 
CHO cells have demonstrated sensitivity to environmental conditions such as heat and Ph, 
relative to yeasts or bacterial hosts. CHO cells have also show a vulnerability to viral 
infection21, which can lead to the loss of entire experimental culture, and requires 
decontamination, or an entirely new culture to avoid re-infection. 
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1.3 Yeasts as a recombinant protein expression host 
Yeasts such as Saccharomyces cerevisiae and more recently Pichia pastoris, are challenging 
the dominance of E. coli. Yeast has been used to produced recombinant proteins by the 
biopharmaceutical industry since 1977, when Novo Nordisk used S. cerevisiae to produce 
human insulin to replace the traditional pig insulin that was used at the time21. By 2012, 
approximately 20% of all protein-based biopharmaceuticals (by mass) on the market were 
produced in S. cerevisiae22.  
There are several reasons to use a yeast cells as the host over a bacterial one when trying to 
express complex mammalian proteins, the most notable of which is the lack of complex PTM 
and post-translational processing within prokaryotes 23, such as complex folding, 
glycosylation, phosphorylation and the removal of signal sequences.24 All these processes 
take place in yeasts. 
There has been a great deal of effort over the last 25 years or so, to improve E. coli as a host. 
Yet despite this, the complex cellular machinery required to properly fold proteins including 
the addition of sugar groups (i.e. glycosylation) or other complex PTMs such as disulphide 
bond formation , remain the domain of eukaryotes such as the yeasts23. Whilst there is 
strong evidence that prokaryotes can perform simple PTMs such as Ser-Thr 
phosphorylation25, the ůĂĐŬŽĨĚĞĚŝĐĂƚĞĚ ‘ƋƵĂůŝƚǇĐŽŶƚƌŽů ?ĐĞŶƚƌĞƐƐƵĐŚĂƐƚŚĞ'ŽůŐŝĂƉƉĂƌĂƚƵƐ 
and endoplasmic reticulum (ER), mean proteins containing more complex PTMs such as 
glycosylation or multiple disulphide bridges, are either of low quality, or are simply 
impossible to produce in a correctly modified and folded state26. The lack of complex protein 
folding and chaperoning systems in prokaryotes also causes the build-up of aggregated, 
misfolded proteins in inclusion bodies. Eukaryotes such as yeast, however, can perform 
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these functions, due to their complex organelle systems. For these reasons, we see an 
increasing number of recombinant proteins are being expressed in yeast, especially for 
larger more complex proteins21 such as MUC1, or human podoplanin, a glycoprotein notable 
for the extensive O-linked glycosylation of its extracellular domain and a platelet-aggregating 
factor respectively27. 
1.4 Expansion of the abilities yeast to produce PTM in recombinant proteins 
Whilst yeasts can produce many of the more complex PTMs seen in human proteins, they 
still lack many of the enzymes required to fully replicate the full range of PTMs found on 
human proteins, most notable of which are the complex glycans. This has necessitated the 
use mammalian cells in these cases, which comes with many associated difficulties (Section 
1.2). It would therefore be ideal to be able to take some of the mammalian enzyme 
pathways and insert them into a host that is easier to work with. It is this line of thought that 
has led to the  ‘humanisation ? of the yeast protein folding machinery28.  
The first few stages of N-glycosylation are identical between the human and the yeast cell: it 
begins with the transfer of N-acetylglucosamine onto dolichol phosphate, on the cytoplasmic 
face of the ER, before it is transported through the membrane, to the lumen face by a 
flipase. More mannoses are added, until Glc3Man9GlcNAc2-Pdolichol is generated, at which 
point the structure is transferred to the target protein at a N-X-S/T motif, and the whole 
protein is sent to the Golgi apparatus. At this point, human cells use the action of several 
1,2-mannosidases29, which cleave the Man8GlcNAc2 glycan present down to Man5-GlcNAc2. 
From there, further modification turns the glycan into a sialylated glycan. The lack 
endogenous 1,2-mannosidases in yeasts means they can only keep adding mannose sugars, 
producing hyper-mannosylated glycans. Hamelton et al29 demonstrated that this hyper-
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mannosylation can be prevented by mutating the genes encoding the enzymes responsible 
for the first mannose added, i.e. the OCH1 and MNN1 genes. By using this as a starting point, 
a novel path was engineered into P. pastoris, that produced sialylated glycan albeit in a 
slightly different way to mammals29. A summary of this path is shown in Figure 1. 
The development of novel pathways for complex N-linked glycosylation has allowed the 
generation of various more complex biopharmaceuticals: for example, there has been much 
research concerning the production of human monoclonal antibodies for pharmaceutical 
Figure 1: A comparative pathway set N-linked glycosylation in human and P.pastoris(a) and 
humanised P.pastoris (b). Inactivating the ALG3 and OCH1 genes stops additional mannose being 
added in P.pastoris, which would normally lead to hyper-mannosylation. Instead, upon reaching the 
Golgi, the simple glycan is converted immediately into GlcNAcMan3, bypass a some of the steps seen in 
human, but ultimately producing the same glycan structure. Figure taken from Hamilton et al29 
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application. Traditionally, recombinant antibodies have been produced by batch fed 
mammalian cell methods, which are both costly, and inefficient30. Attempts have been made 
to remedy this by the development of transgenic plants and animals for monoclonal 
antibody production with the protein being successfully expressed in plants30 and the milk of 
transgenic goats31. However, we now have the ability to produce different monoclonal 
antibodies in a range of different yeast hosts for both research and pharmaceutical 
purposes1,32,33.   
1.5 The use of different yeast species. 
A major improvement in recombinant protein production came in 198534 with the 
harnessing of alternatives to the original S. cerevisiae i.e. the methylotrophic yeast Pichia 
pastoris. This species of yeast holds a few advantages over S. cerevisiae. Firstly (and 
primarily) its ability to use methanol as a carbon source, which is driven by two genes: 
AOX1 and AOX235 both of which are strongly induced by the presence of methanol in the 
culture medium. Using either of these genes allows any plasmid inserted to have a built in, 
easily activated, high efficiency promoter. P. pastoris can also be easily genetically 
manipulated35. Since the mid-1980s numerous yeast species have been used as expression 
hosts, a few examples of which can be seen in Table 1, each with specific advantages and 
draw backs. These yeast species can all be genetically manipulated relatively easily, which 
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Table 1: A selection of yeasts species and the date when they were first used as a 
host for recombinant proteins. Each strain has a specific trait, or traits, which 
renders it useful in a particular situation. 
Species name First described Example protein expressed 
Saccharomyces cerevisiae  1977 Insulin 
Pichia pastoris 1985
34 single-cell protein 
Schizosaccharomyces pombe 199436 Human lipocortin I 
Hansenula polymorpha 199437 human urinary plasminogen activator 
Candida boidinii 199638 Fungal glucoamylase 
Pichia methanolica  199839 Human glutamate decarboxylase 
1.6 Strategies for optimisation protein production 
1.6.1 Manipulation of the quality control system 
The major bottleneck in recombinant protein production in yeasts is in their secretion from 
the cell which can reduce the effective level of protein production by as much as 1000-fold24. 
One of the main factors affecting this secretion is the so called  ‘quality control ?40 systems 
that are so important to the production of  complex PTMs. These quality control systems 
involve multiple complex enzyme pathways, often in the ER, which ensure proteins are 
correctly translated and folded, and function at both the mRNA41 and protein level. The large 
number of enzymes and chaperons involved in these pathways make it difficult to modify 
effectively. Despite this there has been much work published on the subject of improvement 
of the quality control system, much of it focusing on the optimisation of S. cerevisiae, the 
18 | P a g e  
 
most prominent of the yeast hosts. The simplest way of speeding up the whole system is to 
over express the enzymes involved: For example, up regulation of certain genes linked to 
ATPase activity (such as the chaperone protein producing genes: SIL1, LHS1, JEM1, and SCJ1) 
via random mutagenesis, leads to enhanced secretion of recombinant human serum 
albumin42 from S. cerevisiae. Overexpression and mutation of the disulphide bond forming 
protein PDI showed a similar increase in protein production in numerous proteins43,44,45, 
presumably caused by the increase in the cells ability to produce disulphide bonds  at a high 
speed. 
1.6.2 Manipulation of growth conditions 
There have been a number of reports on the effects of stress on yeasts and the vast 
metabolic changes that occur when a cell is stressed, whether that is thermal stress, 
oxidative stress or osmotic stress. Harnessing these changes is a fruitful and rapidly evolving 
avenue of research. Heat stress is the most common target for investigation, as the heat 
shock proteins are heavily involved in refolding of proteins that have become denatured 
during heat stress. Mutating endogenous genes, to exploit these stress responses, can 
increase the speed of protein folding, and so the speed of protein production.  For example, 
Hou et al. 46 showed, that by mutating the heat shock gene HSF1 to be constituently active, 
they induced ƚŚĞ ĐĞůů ?Ɛ ŶĂƚƵƌĂů ŚĞĂƚ ƐŚŽĐŬ ƌĞsponse. By putting the cell into such a stress 
recovery state, the folding of some proteins, such as ɴ-amylase (an enzyme that can be used 
in industrial ethanol production47) can be increased by up to 75%46. However, this does not 
work for every protein; for example, human insulin precursor shows little to no 
improvement in production levels46 in the same mutant strain. 
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Growth conditions such as temperature may also have an effect on recombinant protein 
expression in yeast: growth in colder temperatures (20 °C rather than the more common 30 
°C for yeast growth) has been show to increase the production of Fab fragments, by as much 
as 3 fold48. Low Ph has shown a similar increase in protein production in P.pastoris49 
There is also a consideration of how the yeast cells should be grown, as most laboratories 
use batch method, on small scales, whereas large industrial growths usually uses fed batch 
methodologies. The effect of this can be quite dramatic with Scheidle et al reporting a 53-
fold increases of GFP secretion in H. polymorpha, when using an batch fed method versus a 
regular batch method50. 
1.6.3 Plasmid copy number optimisation 
The link between gene copy number and protein production and secretion has been long 
established, whether by using a plasmid-based strategy or chromosomal integration of 
multiple gene copies51. However, putting a large number of plasmid copies into a cell causes 
a great deal of metabolic stress, and means more resources are diverted away from normal 
metabolic operation, such as reproduction52. Unfortunately, the exact effect of strain ploidy, 
copy number, plasmid burden, selection marker, and promoter selection on the host cell all 
remain uncertain.53  
Despite the lack of a precise understanding of the underlying mechanism of metabolic stress 
caused by large numbers of plasmids, much reserch has been done to establish the exact 
copy number at which the highest level of the target protein can be produced. This number 
is dependent on the host, the plasmid used and the relative complexity of the protein in 
question. For example, in S. cerevisiae , expressing porcine insulin precursor (PIP), the 
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optimum plasmid copy number is 1254, whereas expressing PIP in P. pastoris shows an 
increased level of secretion up to (and possibly above) 18 copies55. 
1.6.4 High-throughput screening for high secretion levels 
The strategies so far described have involved discrete and often pre-planned changes, each 
using a limited number of species and growing up cells in batches. These types of methods 
for the improvement of recombinant protein secretion in yeasts are not the only way to 
improve secretion of desired proteins. An alternative strategy is to screen a great many 
individual strains for the desired trait i.e. high through-put screening (HTS). For example 
each member of a large library of cells could have random mutations introduced by one of 
serval methods (degenerated oligonucleotides, chemical mutagenesis or, the most popular, 
error-prone PCR), with these mutation often being targeted to a specific gene56. The main 
limit of this process is the rate at which the mutant library can be screened, which 
determines the size of the library generated, and so the chance of identifying a novel strain 
at the high end of the secretion rate bell curve56. HTS can have a drastic effect on secretion 
levels of recombinant proteins, Huang et al showed a 6 fold increase in the secretion of 
recombinant ɴ-amylase, in strains of S. cerevisiae  mutated with UV light, against a control 
strain57.  
1.6.5 Use of non-domesticated yeast strains 
An alternative approach to the problem of generating more efficient recombinant protein 
secreting strains is looking at understudied wild strains of yeast, which have had minimal 
human exploitation, and as a result have undergone no genetic manipulation. Analysis of 
these strains has shown to have a large genetic diversity58. Such strains may show a great 
efficiency in their secretion abilities; these strains may naively secrete the endogenous 
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protein Killer toxin (KT) (Section 1.7), which would lead them to have the necessary 
machinery in place, which could be harnessed in recombinant protein secretion.  
By looking at the secretion related phenotypes of these strains, using a model secreted 
protein we can identify strains with enhanced protein secreting abilities. It is from this core 
idea that this current project comes; bǇĐŽŵƉĂƌŝŶŐƚŚĞƐĞƐƚƌĂŝŶƐ ŝŶƚŽƐŽŵĞ  ‘ƐƚĂŶĚĂƌĚǁŝůĚ
strains ?/ŚŽƉĞƚŽŝĚĞŶƚŝĨǇĂƐĞƚŽĨƵƐĞĨƵůƐƚƌĂŝŶƐ ?ǁŚŝĐŚĂƌĞĂďůĞƚŽĞĨĨŝĐŝĞŶƚůǇƐĞĐƌĞƚĞĐŽŵƉůĞǆ
disulphide bonded proteins. Once this set of strains has been identified, the next stage of 
later projects would be to perform genetic and biomolecular analysis and identify the core 
differences responsible for these phenotypes.  
1.6.6 The wild strains used in this project 
For this project a collection of 21 wild strains were used. The majority of these strains come 
from parts of China; largely from the mountainous forest covered island Hainan, just off the 
south-western coast of the Guangdong province and have been isolated from tree bark.  In 
addition there are strains isolated from the Ecuador and Slovakia, from river beds and 
insects. This diverse range of yeasts should produce a large range of phenotypes, and is a 
fertile ground to start looking for new  ‘ƐƵƉĞƌ secreting ? strains. 
1.7 Killer toxin 
This project required a model protein that was secreted from the cell, have a simple and 
reliable bioassay, and contain post translation modifications. The pore-forming toxin59 K1 
Killer Toxin, a 19.088 kDa60  heterodimer containing 3 disulphide bonds  was chosen. K1 is 
one of three killer toxins that are found in S. cerevisiae, the others being K2 and K28. K1 KT 
also has a simple assay, called the halo assay, which is described in section 2.5.1 
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1.7.1 Biosynthesis of the mature killer toxin 
The pre-pro toxin (Figure 3A) consists of 5 components: a  ‘ƉƌĞ ?signal sequence, a small delta 
chain and the pro-toxin, which is made up of the alpha beta and gamma chains. Production 
of the mature protein requires processing in the Golgi apparatus, and ER. In the ER the alpha 
and beta chains61 are bonded with disulphide bonds at residues 92 to 248, 95 to 312 and 107 
to 239 (Figure 3B) and the gamma chain is N-glycosylated in three places. The pro-toxin is 
then transported to the Golgi where it is cleaved into each individual chain by the enzyme 
Kex2p ?ĂŶĚƚŚĞŶƚŚĞƚĞƌŵŝŶƵƐŽĨƚŚĞɴ-chain is trimmed by the carboxypeptidase Kex1p, to 
create the secreted toxin (Figure 4). This pathway is shared by all 3 toxins, though the 
amount of disulphide bonds differs between each toxin62.  
 
Figure 3; Schematic diagram of the K1 pre-pro toxin as well as the mature toxin. A; The unprocessed 
pre pro toxin as translated from the mRNA. The start residue for each region are noted. B; The mature K1 
killer toxin, with position of disulphide bounds noted. 




The gamma, immunity, chain, undergoes 3 N-linked glycosylation events (residues 181, 203 
and 216) and, whilst part of the pro-toxin, confers immunity against the toxin, by binding to 
the cytoplasmic side of the transmembrane protein which is targeted by the secreted toxin, 
blocking the toxins action.  
Immunity to the toxin being co-expressed by the same gene as the toxin is a key factor of 
choosing KT. Whilst some toxins require a separate gene to encode an immunity protein, this 
Figure 4; Schematic of the processing undergone by killer toxin. This process is shared between the 
three different yeast killer toxins. Figure taken from Schmitt et al62 
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is not the case in KT, meaning a single cassette containing both toxin and immunity chain can 
be transformed into a given strain, and so toxicity from the product is not something we 
have to consider. This is not the case in all recombinant proteins, as there are examples of 
recombinant proteins that have toxic effects on the host system23. 
The complex post translational processing required by this protein makes it a good model 
protein for testing the secreting abilities of these strains, as the ability to make such 
modifications is one of the key reasons to use yeasts for recombinant protein secretion.  
1.7.2 Mechanism of action for K1 Killer toxin 
The secreted, K1 KT ďŝŶĚƐ ƚŽ ƚŚĞ ĐĞůů ǁĂůů ŐůƵĐĂŶ ƌĞĐĞƉƚŽƌ ɴ-1,6-D63, which transports the 
toxin inside the target cell. Once inside the cell, the toxin binds to the plasma membrane 
receptor Kre1p, and forms a cation-selective ion channel in the membrane, which leads to 
cell death. At higher concentrations (>10pM), the toxin may bind to Tok1p, and which in turn 
activates Yca1p and Dnm1p, which leads to mitochondrial ROS generation which eventually 
leads to cell death via Reactive oxygen species build up and stimulating apoptosis 63. 
1.7.3 Killer toxin dsRNA virus 
KT is the only endogenous protein that is naturally secreted by some strains of S. cerevisiae 
which contains complex PTMs, making it an ideal candidate for testing in the wild strains: it 
may be the case that some of these wild strains already have the toxin, and so have the 
machinery in place to secrete proteins with PTMs. Natively, K1 KT is encoded on a dsRNA 
virus which infects S. cerevisiae cells called M1, with the K2 and K28 toxin being encoded on 
the M2 and M28 viruses respectively. M1, M2 and M28 are satellite virus maintained by a 
second dsRNA virus called the L-A virus. the viral pair are coated by 60 76-kDa dimer 
proteins called Gag, and a  171-kDa fusion protein consisting of  Gag and a second protein 
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Pol62. The viral RNA is replicated and a single stranded RNA is extruded into the cytoplasm. 
The Gag-Pol fusion protein binds to this RNA and acts as a nucleating point to form a new 
viral particle. In this way the virus replicates inside the cell, without causing cell lysis.  
1.8 Aims of the project 
By using the Halo assay to measure KT, a quantitative value for the secretion abilities of the 
wild strains can be generated. To do this technology to insert a cE ‘ŐĞŶĞ ?ŽĨ< ?KT  was 
developed. These technologies included a method of insertion into strains, lacking 
auxotrophic markers. The assay for KT was also developed, along with analysis of the 
secretome of transformed strains. A set of domestic strains were also assayed for their 
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2. Materials and Methods 
2.1 Yeast strains 
Table 2.1 Summary of all standard strains of S. cerevisiae used 
Strain name Genotype Notes 
S6 DdɲŚŝƐ ?ȴ ?leu2ȴ ?lys2ȴ ? 
ura3ȴ ? 
Lab strain, Killer toxin sensitive, from 
Kent fungal group 
Ski4 mutant Ddɲ ?ƵƌĂ ?ȴ ?, ski4-164 Lab strain, Super Killer producing strain, 
from Kent fungal group 
BY4742 DdɲŚŝƐ ?ȴ ?leu2ȴ ?lys2ȴ ? 
ura3ȴ ? 
Standard Lab strain, from Kent fungal 
group 
3883 DdĂƵƌĂ ?ȴ ?ůĞƵ ?ȴ ?ůǇƐ ?ȴ0 
ŵĞƚ ? ?ȴ ?
Modified wild-type isolate, European 
wine strain 
3893 DdĂƵƌĂ ?ȴ ?ůĞƵ ?ȴ ?ůǇƐ ?ȴ ?
ŵĞƚ ? ?ȴ ?
Modified wild-type isolate, West African 
strain 
3903 DdĂƵƌĂ ?ȴ ?ůĞƵ ?ȴ ?ůǇƐ ?ȴ ?
ŵĞƚ ? ?ȴ ?
Modified wild-type isolate, North 
American Strain 
3913 DdĂƵƌĂ ?ȴ ?ůĞƵ ?ȴ ?ůǇƐ ?ȴ ?
ŵĞƚ ? ?ȴ ?
Modified wild-type isolate, Sake strain 
3923 DdĂƵƌĂ ?ȴ ?ůĞƵ ?ȴ ?ůǇƐ ?ȴ ?
ŵĞƚ ? ?ȴ ?
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Table 2.2 Summary of all experimental wild  strains of S. cerevisiae used 
Strain name Geographic source Biological source 
21 Ecuador, Los Rios  Beetle 
27 Ecuador, Rumipamba forest  Grass 
60 Ecuador, Podocarpus national park  Hemipteran insect 
99 Slovakia, Bratislava  Danube river water 
111 Slovakia, Bratislava  Plum tree leaf 
114 Slovakia, Bratislava  Peach tree leaf 
BJ20 China; Northern china, Secondary forest  Fruit 
BJ6 China; Northern china, Secondary forest  Fruit 
BT14 Unknown providence Unknown providence 
FJ7 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
HN10 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
HN11 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
HN14 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
HN15 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
HN16 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
HN2 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
HN6 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
HN9 China; Hainan, Primeval forest Rotten wood and bark of fagaceae trees 
SX1 China; Shaanxi province Oak isolates 
SX2 China; Shaanxi province Oak isolates 
SX6 China; Shaanxi province Oak isolates 
28 | P a g e  
 
Strains were grown to stationary phase, (72 hrs in a shaking incubator at 30°C) and stored in 
suspensions of 500Pl of 40% glycerol and 500Pl of YEPD in sterile cryo-tubes and then stored 
at -80°C. Strains were then revived by inoculating into a liquid YEPD media, and grown at 
30°C for 48 hrs.   
NB: Throughout this thesis, the novel wt strains are collectively referrĞĚƚŽĂƐƚŚĞ ‘tŝůĚ
ƐƚƌĂŝŶƐ ?ǁŚŝůƐƚƐƚƌĂŝŶƐ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?ǁŝůůďĞƌĞĨĞƌƌĞĚƚŽĂƐƚŚĞ ‘ĚŽŵĞƐƚŝĐĂƚĞĚ
ƐƚƌĂŝŶƐ ? ?^ƚƌĂŝŶƐz ? ? ? ? ?^Ŭŝ ?ĂŶĚ^ ?ĂƌĞƐƚĂŶĚĂƌĚůĂďŽ ĂƚŽƌǇƐƚƌĂŝŶƐ 
2.2 Plasmids used 




Main features Selection Source 
pVT100u  Killer toxin gene (ADH1 promoter) URA3 (Yeast),  Ampicillin 
Resistance (E. coli) 
H. Bussy, McGill University, 
Montreal Canada  
pML107 Cas9/gRNA plasmid LEU2 (Yeast), Ampicillin 
Resistance (E. coli) 
John Wyrick Lab 
(Unpublished) 
RHx702 Hygromycin B drug resistance 
gene 
Hygromycin B drug 
resistance (Yeast),  
Ampicillin Resistance (E. 
coli) 
Randal Hoffman 
pUKC3546  Killer toxin gene (ADH1 promoter),  
Hygromycin B drug resistance 
Hygromycin B drug 
resistance, Amp. 
Novel plasmid generated 
in this study: modified 
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2.3 Growing yeast and Escherichia coli 
2.3.1 Yeast medium  
Table 2.4 gives a summary of the medium used for growing yeast. All media was sterilised in 
an autoclave for 45 mins (Classic Media, prestige medical) before use. Where agar plates 
were required, 2% granulated agar was added before autoclaving. For auxotrophic selection, 
Synthetic Defined (SD) media was used, however, instead of synthetic complete mixture; 2% 
of the relevant mixture was substituted in (e.g., ura drop out mixture for  Wura plates).  
 
gene Resistance (E. coli) RHx702 
pCG495 Gaussia luciferase (ADH1 
promoter) 
URA3 (Yeast),  Ampicillin 
Resistance (E. coli) 
Campell Gourly lab, Kent 
Fungal Group 




2% glucose (G/0500/61, Fisher scientific) 
0.67% Yeast nitrogen base (291940, BD) 
2% synthetic complete mixture (DSCK1009, Formedium LTD) 
 
YEPD 2% glucose (G/0500/61, Fisher scientific) 
1% yeast extract (212750, BD) 
2% bactopeptone (211677, BD) 
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2.3.2 E.coli medium  
Table 2.5 gives a summary of the components in the medium used for growing E.coli. All 
media was sterilised in an autoclave before use. Where agar plates were required, 2% 
granulated agar was added. Ampicillin resistance was often used as a selective marker for 
transformations, in which case 100 µg/ml filter sterilised Ampicillin was added after 
autoclaving. For long term storage, a stock solution of 100mg/ml, suspended in distilled 
water was made 
2.4 Molecular Biology techniques 
2.4.1 Yeast transformations 
Yeast transformation were done using a standard LiAc protocol65, before being grown on 
agar plates with a different selection marker depending on the plasmid used. For this, cells 
were taken from a single colony on an existing agar plate and grown to log phase in YEPD 
liquid media for 24 hrs at 30°C in a shaking incubator. 2ml of culture was taken, and spun at 
4000 rpm for 5 mins, and the supernatant removed via pipetting. The cells were 
resuspended in 240Pl of 50% PEG, and transferred to sterile 1.5ml Eppendorf tubes. A 
master transformation mix was made up (Table 2.6), and 85.5 Pl of this mix was added to 
each Eppendorf tube. The pellet was re-suspended. The cells were then incubated at 30°C 
for 45 mins, before being incubated for a further 45 mins at 42°C. Cells were then spun down 
Table 2.5 Summary of all medium used for  E.coli 
LB 1% tryptone (211705, Becton, Dickinson and company (BD)) 
0.5% yeast extract (212750, BD) 
1% NaCl (S/3160/60, Fisher scientific) 
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at 2000rpm for 5 mins, and the supernatant was removed. The cells were resuspended in 
150Pl of sterile water and plated onto appropriate selective agar plate. 
 
Table 2.6; the components required for a single yeast transformation mix.  
Component Amount 
1M LiAc 36 Pl 
Sterile distilled water 34 Pl 
Single stranded DNA 10Pl 
Plasmid  3Pl (300-600ng) 
2-Mercaptoethanol 2.5ul  
 
2.4.2 E.coli transformations 
To increase the amount of any of the plasmids used , 20Pl of Super Competent cells66 from a 
-80 °C stock was taken and kept on ice. 200ng of the plasmid was then added. Initially, cells 
were left for 5 mins on ice after the addition of the DNA. The cells were then plated onto LB-
amp plates, and grown at 37 °C for 24 hrs. This method, however produced very low 
efficiency (100 cfu/Pg) when using any of the plasmids listed in table 2.3. To counter this, 
after the plasmid DNA was added, the cells were gently mixed and then left on ice for an 
hour. 5Pl of LB was then added and the cell suspension was left for a further 2 hrs. This was 
enough to raises the efficiency to typically 109 cfu/Pg. 
2.4.3 Plasmid purification from E.coli  
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Successfully transformed E.coli cells were inoculated into 20ml of LB media and incubated 
overnight at 37° C in a shaking incubator. The Qiagen QIAprep Spin Miniprep Kit was used to 
extract and purify DNA of interest. 
2.4.3 PCR 
2.4.3.1 Primer design, and PCR conditions  
PCR was done using pairs of oligonucleotide primers (table 2.7) designed with the online 
ƚŽŽů ‘WƌŝŵĞƌ ? ?67 with any required cut sites added in as necessary. A Techne TC-312 PCR 
Thermal Cycler was used for the amplification. The annealing temperature and extension 
time of each reaction was demined by the primers and products respectively. The annealing 
temperature was set at 5°C below the melting temperature of the section of the primers 
homologues to the plasmid; this does not include any added cut sites. The extension time 
was calculated at 1 min per kB of the final product. 
Table 2.7 The sequences used in PCR as primers 
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2.4.3.2 Killer toxin cloning PCR 
 KT_clone_pci1_f and KT_clone_xho1_r are primer pairs cloning the killer toxin gene into 
RHx702. Both of these primers consisted of a stretch of 80 bases that pair to the region 
either side of the  cut site in the yeast genome(marked in red in table 2.7), as well as adding 
a 6 base pair cut site (Pci1 and Xho1 respectively), to be added (marked in green in table 
2.7). For this reaction, 100 ng of pvt100, 5Pl of 10x taq reaction buffer, 200 µM dNTPs, 
0.2uM of both KT_clone_pci1_f and KT_clone_xho1_r, were added to 1.25 units of taq 
polymerase. The mix was then made up to 50Pl with sterile distilled water. PCR conditions 
were as follows: 
Stage Temperature Time (sec) 
Initial denaturation  95°C 300 
30 cycles of: 
Denaturation 95.0°C  30 
Annealing 53.4°C  45 
Extension 68.0°C  210 
  
Final extention 68.0°C  600 
 
To check the size of, and purify the PCR product, the completed reaction was run on an 
agarose gel (Biolaboratories LTD , batch number :F25073). The gel was run at 75 volts for 45 
mins, and used ethidium bromide (final concentration 0.5 Pg/ml) to visualise the DNA, on a 
transilluminator. Once the band was compared in size to a marker, and confirmed to be of 
the size predicted by Primer3, the band containing the product was cut out, and gel purified 
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2.4.3.3 Generation of CRISPR repair template with PCR 
The repair templates used in the CRIPSR genome editing, were generated by PCR using the 
two primer pairs CRISPR_RT_P1a/ CRISPR_RT_P1b and CRISPR_RT_P2a/ CRISPR_RT_P2b.The 
sequence for these primers can be found in Table 2.7, with the region that pairs with the KT-
encoding sequence of PVT100 coloured in blue. The target sequence is highlighted in red. 
The region highlighted in green is an inserted stop codon. See Figure 2.1 for a diagram of 
how the primers paired to both the genome and the plasmid. The mix for both sets of PCR 
were 100 ng of pvt100, 5Pl of10x taq reaction buffer, 200 µM dNTPs, 0.2uM of both forward 
(CRISPR_RT_P1a and CRISPR_RT_P2a)  and reverse primers(CRISPR_RT_P1b and 
CRISPR_RT_P2b)  , were added to 1.25 units of Taq polymerase before being made up to 
50Pl with autoclaved distilled water. The conditions for each PCR were as follows: 
Stage Temperature Time (sec) 
Initial denaturation  95°C 300 
30 cycles of: 
Denaturation 95.0°C  30 
Annealing 53.4°C  45 
Extension 68.0°C  210 
  
Final extention 68.0°C  600 
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2.4.4 CRISPR target site and plasmid 
When designing the CRISPR experiment, the target locus for gene insertion was identified 
ƵƐŝŶŐ ‘,KW,KW ?68. CHOPCHOP outputs the best guide RNA to use to target specific loci.  
The guide RNA oligo was designed with a pair of restriction enzyme cut sites (BclI/SwaI) 
which allowed insertion into the pML107 plasmid at the correct locus. Both the plasmid and 
the primers were digested in the same way: SwaI was used first, incubated at 25°C for 1 hr, 
before being heat inactivated at 65°C for 40 mins. BclI was then added and incubated at 50°C 
for a further 1 hr. The cut fragment was then run on an agarose gel (75 volts for 45 mins, and 
used ethidium bromide (final concentration 0.5 Pg/ml) to visualise the DNA, on a 
transilluminator), and gel purified using a GeneJET Gel Extraction Kit (ThermoScientific). The 
Figure 2.1; Generation of CRISPR repair template with PCR. Primer map in terms of homology to both the 
killer toxin gene (in this case, in pVT100u) and the target loci in the yeast genome. Primer pairs have the 
same colour .Primers P2a and P1a have homology to both pVT100u and to the target in the genome. Primers 
p1a and p1b leads to the generation of a repair template with an inserted stop codon: once integrated into 
genome, this will produce a truncated AIR carboxylase (the product of the ADE2 gene) protein. 
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two fragments were then ligated with 1 Weiss units of T4 ligase, in a molar ratio of 3:1 inert 
to vector, made up to 30Pl with water. The reaction was incubated for 16 hrs at 25°C.  
To generate the repair template, PCR using the primer pairs p1a/p1b and p2a/p2b were 
separately run, using pVT100 as a template, cloning of the killer toxin region. Once 
generated, the repair template and the Cas9/gRNA plasmid were transformed into the 5 wild 
strains, which were then plated out on SD plates deficient in leucine, and grown overnight at 
30°C 
2.4.5 Agaroses gel electrophoresis 
During this project, agaroses gel electrophoresis was used for a range of reasons (PCR 
product checking, Ligation/restriction digest checking, etc.). Whilst the reasons for its use 
may differ the underlying method remained the same. 
A 1-2% w/v (with concentrations near 2% being used for short DNA sequences, and nearer 
1% for larger sequences) solution of agarose and TBE buffer (10 M EDTA, 0.04 M Tris-acetic 
acid [v/v]) was prepared. Typically a final volume of 50ml was used. This solution was heated 
in a microwave, until the agarose was completely dissolved (typically 30-45 seconds), then 
the solution was left to cool to 50 °C. Ethidium bromide was then added to a final 
concentration of approximately 0.2- ? ? ?ʅŐ ?ŵ>, before the gel was poured into a gel cast, 
with a comb to form the wells. Bubbles were popped with a clean metal spatula, to ensure a 
smooth, even gel.  
Once the gel had set, it was submerged in TBE, until completely covered. Samples were then 
loaded into the wells, along with an appropriate marker (in this project, GeneRuler 1 kb Plus 
DNA Ladder from ThermoFisher scientific was used) and the gel was run at 95 volts for one 
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hour, or until the dye front had reached the bottom of the gel. The DNA in the gel was then 
visualised using a UV- transilluminator. 
2.4.6 Gel purification 
Once useful fragments were identified (generally via comparing the size to an expected 
value, e.g. plasmid size), the DNA was purified from the gel. This was done using a QIAquick 
Gel Extraction Kit, following the protocol included with the kit. This typically produced a DNA 
concentration of ~ 50-300ng/Pl, (depending on the initial concentration run on the gel) 
suspended in elution buffer. This concentration was tested on a NanoDrop microvolume UV-
Vis fluorospectrometer(NanoDrop 3300, Thermo Scientfic). 
2.4.7 Restriction digests 
To digest a plasmid, the correct restriction enzyme was identified using serial cloner. Then a 
mixture was made up as following: 1 µg DNA,1 µL of each Restriction Enzyme, 3 µL 10x 
digest buffer, up to 30µL with distilled H2O.   
The buffer used was one of the NEBuffers depending on the enzymes being used. This was 
identified using the New England Biosciences web tools.  The mix was then incubated at 
room temperature (25 °C) overnight (8-18 hours). Enzymes were heat inactivated at 65°C.  
To check for successful digestion, the mix was run on an agarose gel, along with a sample of 
intact DNA as a control. Gel was then inspected using a UV- transilluminator. 
2.4.8 Ligation 
To insert fragments into a vector, T4 DNA ligation was used.  For this, a mix was made on ice 
of a ~1:3 mass ratio of vĞĐƚŽƌƚŽŝŶƐĞƌƚ ?ĂůŽŶŐǁŝƚŚ ?ʅůd ?E>ŝŐĂƐĞƵĨĨĞƌ ? ? ?y ? ? ?ʅůŽĨd ?
DNA Ligase. The T$ ligase was added last, and kept at -20 until needed, before being quickly 
returned to the -20 freezer  dŚĞƐŽůƵƚŝŽŶǁĂƐŵĂĚĞƵƉƚŽ ? ?ʅůǁŝƚŚĚ,2O. Mix was 
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incubated at room temperature (25 °C) overnight (8-18 hours). Ligation was check via gel 
electrophoresis, using an unligated sample as a control.  
 2.5 Assays for secreted proteins 
2.5.1 Halo assay for Killer toxin 
To quantitate the level of KT secreted from a giveŶƉƌŽĚƵĐŝŶŐƐƚƌĂŝŶ ?Ă ‘ŚĂůŽ ?ĂƐƐĂǇǁĂƐƵƐĞĚ ?
This assay works on the susceptibility of a sensitive strain of S. cerevisiae (in this case the S6 
Strain; Table 2.1); 25ml of a top agar (a full break down of components is listed in Table 2.8) 
containing the 5x106 cells/ ml in mid log phase of a sensitive strain was poured over 100 ml 
of a base (a full break down of components is listed in Table 2.8) containing 0.15M 
Methylene blue. 
/ŶŝƚŝĂůůǇĂ ‘ĐůĞĂƌĞĚŵĞĚŝĂ ?ĂƉƉƌŽĂĐŚǁĂƐƚƌŝĞĚ PƚĞƐƚƐƚƌĂŝŶƐǁĞƌĞŐƌŽǁŶŝŶĂŶ^D selective 
media, for 12 hours. The OD600 was measured, and each test strains was diluted down to  
OD600  =  0.8 . The media was then cleared of cells via centrifugation (4000rpm, 5 mins)  and 
15ul of this cleared media was pipetted into 6mm  filter disks, and incubated for 3 days at 
25°C. This method however, produced inconsistent results, with halos often being very 
ƐŵĂůů ?/ŶĂŶĂƚƚĞŵƉƚƚŽƉƌŽĚƵĐĞŵŽƌĞĐŽŶƐŝƐƚĞŶƚƌĞƐƵůƚƐ ?ĂŶĂůƚĞƌŶĂƚŝǀĞ ‘ǁĂƐŚĞĚĐĞůů ?ŵĞƚŚŽĚ
was tried; 1 ml of the test strain (at OD600  =  0.8, i.e. log growth phase) was taken,  as 
before,  spun down and resuspended in 10Pl of ddH2O.  This suspension was then pipetted 
onto 6mm filter disks and incubated at 25°C for 3 days (figure 2.2). This method produced 
more consistent results, so was used for the remaining assays. 
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During the 3 day incubation of the washed cell method, the tests strains secrete KT, which 
causes the cell from the sensitive strain to die. The methylene blue is then taken up by the 
dying cells, producing a dark blue ring surrounding the zone of clearing. Plates were then 
scanned and the image analysed with  “ŝŵĂŐĞ: ? ?Ă:ĂǀĂ-based program which allows the size 
of components of an image to be analysed and compared. For each test plate, 
untransformed BY4742 and SKI4 strains (Table 2.1) were used as negative and positive 
controls respectively. The recipe for the agar used can be found in table 2.8 
 
Table 2.8 The two agars used in the zone of clearing assay 
Zone of clearing 
assay base agar  (pH 
4.6 - 4.8) 
0.5% yeast extract (212750, BD) 
0.5% bactopeptone (211677, BD) 
1.5% Citric Acid(251275-500G, Sigma-Aldrich) 
1.5% agar (214530, BD) 
2% glucose (G/0500/61, Fisher scientific) 
0.625% 0.15M Methylene blue(added after autoclaving, filter sterilised ) 
Figure 2.2; construction of the zone of clearing assay plates. Base agar is mixed with 
Methylene blue, and the top agar is doped with S6 sensitive yeast.Dyijng cells in the top layer 
absorbed the blue from the bottom, leading to the formation of hales around the test strains 
on the filter disks. 6mm disks were used, with 10Pl of OD600 0.8 test strain. 
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2.5.2 Gaussia Luciferase luminesce assay 
Once strains were transformed with plasmid pCG495 (Table 2.3) they were grown overnight 
at 30°C.  A Pierce Gaussia Luciferase Glow Assay Kit (Catalogue number: 16160) was then 
used. Protocol was followed as included in the kit. A 96 well plate was used (Figure 2.3); 20 
Pl of cell cleared media was taken and added to 50 Pl Working Solution (100:1 Gaussia 
Luciferase Glow Assay Buffer: 100X Coelenterazine) in each test well, and was then 
incubated at 25°C for 10 mins. 
 Once the substrate (coelenterazine) was added, florescence readings at 482 nm (the peak 
emission of the catalysed reaction Gaussia Luciferase) were taken in a plate reader 
(FLUOstar Omega Microplate Reader - BMG LABTECH) every 10 mins for 1 hr. Values were 
exported to Excel for further analysis; repeat runs were averaged, and standard error was 
calculated.   
 
 
1.42% Na2HPO4 (S3264-500G) 
Zone of clearing 
assay  top agar  
(pH 4.6 - 4.8) 
0.5% yeast extract (212750, BD) 
0.5% bactopeptone (211677, BD) 
1.5% Citric Acid (251275-500G, Sigma-Aldrich) 
0.75% agar (214530, BD) 
2% glucose (G/0500/61, Fisher scientific) 
1.42% Na2HPO4 (S3264-500G, Sigma-Aldrich) 
5x106 cells /ml S6 (added after autoclaving, and cooling to 45 °C.) 









2.5.3 Hygromycin B resistance assay  
Hygromycin B is a anti-biotic which is effective against both prokaryotic and eukaryotic cells 
functions to stop translation of proteins by binding to the S30 ribosomal sub unit. The 
residue it binds to (H44), has been implicated in the movement of tRNA from the A site to 
the P-site, which in turn cases a stalling of protein production.69 
To determine the level of Hygromycin B that should be used when selecting for 
transformation by the plasmid pUKC3546 (Table 2.3)  each strain was grown on 3 different 
YEPD plates, each with a different concentration of Hygromycin B added after autoclaving; 
200 ug/ml, 1000 ug/ml, 2000 ug/ml. Each strain was grown overnight, and then diluted to 
OD600 0.01. 10Pl of each strain was then plated out, and grown for 72 hrs at 30 °C.  
Some strains had low numbers of colonies growing on 2000 Pg/ml. To test the ability of 
these strains to produces resistant colonies, 105 cells (determined using a haemocytometer) 
were suspended in 10Pl YEPD and plated out onto a 2000 Pg/ml hygromycin B plate, and 
grown for 6 days. The amount of colonies that displayed resistance was then scored. 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A T1 T1 T1 T1 T1 T1 B B B B B B 
B T2 T2 T2 T2 T2 T2 B B B B B B 
C T3 T3 T3 T3 T3 T3 B B B B B B 
D T4 T4 T4 T4 T4 T4 B B B B B B 
E T5 T5 T5 T5 T5 T5 B B B B B B 
F Cp Cp Cp Cp Cp Cp B B B B B B 
G Cn Cn Cn Cn Cn Cn B B B B B B 
H B B B B B B B B B B B B 
Figure 2.3; layout of the 96 well plates for Gaussia Luciferase assay. T1-5 was each test strain 
(in order: 3903, 3913, 3923, 3883, and 3893). Cp was the positive control: BY4742 
transformed with the plasmid. Cn was the negative control: BY4742 with no plasmid. B 
represents blank wells which remained empty. 
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2.5.4 Plasmid stability assay 
To test the stability of pvt100u within yeast strains, an assay was developed where 
transformed strains would be grown in non-selective liquid media (YEPD) for 24 hrs at 30°C. 
10Pl of media were taken and plated out onto both SD  Wura and SD agar plates. Plates were 
incubated for 3 days at 30°C. Colonies for an individual strain, on both plates were counted 
and compared. 
2.6 secretome analysis 
To check the secretome of the domesticated strains, both untransformed and transformed 
with pvt100, the strains were grown in YEPD liquid media for 72 hrs at 30°C in a shaking 
incubator. The culture was then centrifuged at 14000 rpm for 15 mins, and 30 ml of culture 
was taken, before undergoing TCA protein precipitation and was then run on an SDS Tris-
Tricine gel. 
 
Table 2.9: Composition of 40ml 1x sample buffer 
Component  amount 
 1 M Tris-HCl pH 6.8 2.5 ml 
SDS 1.0 g  
0.1% Bromophenol Blue 0.8 ml 
100% glycerol 4 ml  
14.3 M 2-mercaptoethanol (100% stock) 2 ml  
H2O up to 40ml 
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 2.6.1 TCA protein precipitation 
30ml growth culture was taken and cleared of cells by 10 min of centrifugation at 4000 rpm 
in sterile 50 ml falcon tubes.  25% by volume (7.5ml in the case of 30 ml cultured media) of 
100% w/v TCA was added. This solution was incubated for 60 mins at 4°C and then tubes 
were spun at 14000 rpm for 60 mins at 4°C. Supernatant was removed, leaving the white 
protein pellet intact. The pellet was then washed with 500Pl of -20°C acetone. Tubes were 
then spun down at 14000 rpm for 5 mins, and the acetone removed via pipetting. This wash 
was then repeated. Once acetone had been removed again, the pellet was re-suspended in 
50Pl of 1x sample buffer (table 2.9), and transferred to sterile 1.5ml Eppendorf tubes. 
Samples were then boiled at 95°C for 15 mins before analysis by SDS-PAGE. 
2.6.2 SDS PAGE analysis 
Protein samples were loaded onto a Tris WTricine gel (Table 2.10). The internal cavity of the 
gel tank was filled with a cathode buffer, and the exterior cavity with an anode buffer. The 
1X cathode buffer was 100mM Tris, 100mM Tricine, and 0.1%SDS, at pH 8.25, stored as a 
10X solution at room temperature. The 1X anode buffer consisted of 210mM Tris pH8.9, 
stored as a 10X solution at room temperature. The gels were run for 18 hrs at 25 volts and 
30 milliamps. Coomassie brilliant blue was used to stain for an hour, and strong SDS distain 
(50% distilled water, 40% methanol, 10% glacial acetic acid) was applied until the gel 
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Table 2.10: Composition of the Tris WTricine polyacrylamide gel (makes 2 gels) 
SOLUTIONS Separating gel  Stacking gel  
Acrylamide Solution (40% Acrylamide 
(36.5:1)) 
10 ml 1 ml  
Gel Buffer (3 M TrisHCl pH8.45 + 0.3% SDS) 10 ml 3 ml 
Glycerol  3 g 0 g 
H2O Up to 30ml Up to 12 ml 
10% APS 100 µl 90 µl 
TEMED 1.0 Pl 9 µl 
  
2.6.3 Lysed cell analysis 
To check the intracellular protein components, both untransformed, and strains transformed 
with pvt100, were grown in YEPD liquid media for 24 hrs at 30°C in a shaking incubator. This 
may lead to a loss of plasmid in a transformed strained; however, the plasmid retention 
assay had already shown that a 24 hr growth in a non-selective media had little to no effect 
on pvt100u retention (section 3.1.2). 50ml of culture was taken and spun down at 4000rpm 
for 5 mins at 4°C. The liquid medium was poured off and the cells were resuspended in 12ml 
sterile distilled water. The cells were then spun down at 4000rpm for 5 mins, before being 
resuspended in 12ml of 1M sorbitol. The cells were once again spun down at 4000rpm for 5 
mins, before being resuspended in 12ml SCE buffer (1 M sorbitol 100mM sodium citrate, 
 ? ?ŵDd ?Ɖ, ? ? ? ? ? ? ? ? ? ?A?ɴ-mercaptoethanol). 120Pl of 1M DTT and 60Pl of 10,000 
units/ml lyticase (SigmaAldrich) were then added, and the solution incubated for 1 hr at 30°C 
in a shaking incubator.  
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The tubes were spun down at 1500 rpm for 10 mins, and the supernatant removed. The 
resultant pellet of spheroplasts were resuspended in 2ml 20% SDS, and incubated for a 
further 10 mins at room temperature. The solution was then spun down at 4000 rpm and 
the supernatant taken and underwent TCA protein precipitation (section 2.6.1), and was run 
on an SDS Tris-Tricine gel (Section 2.6.2). 
2.7 Computational analysis: ImageJ 
To analyses the data from the plates generated in the halo assays (Section 2.5.1), the Java-
based image analysing program ImageJ70 was used. ImageJ allows users to measure the size 
of various features of a given image; by measuring the size of the halo and expressing it as a 
percentage of the size of the plate on the image, a measurement of the size of the halo 
could be made. The next step was to then measure the size of the actual plate, and using the 
percentage from before to calculate the size of the zones of clearing. By following this 
method, consistent measurements were made, and most importantly, measurements 
between different plates could be compared. 
 
3. Results 
3.1 Domestic strains: transformation and halo assay 
To optimise the halo assay for KT secretion, the five domesticated strains were used as well 
as BY4742 and Ski4. They were first transformed with pVT100u using the LiAc method 
(section 2.4.1) and then plated onto the halo assay plates. The stability of this 
transformation was also tested, to check if the plasmid would be lost over time, if grown on 
non-selective media. 
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3.1.1 Successful transformation using the LiAc method 
Strains were transformed with at least 200ng of pVT100u, following the method outlined in 
section 2. The selection plate used was a SD plate without uracil; this was because the 
domestic strains had the  genotype, meaning they could not produce uracil. If grown 
on or in a medium which lacked uracil these strains would die, however pVT100u contained 
the URA3 gene, so any cells successfully transformed would be able to grow, whilst any cells 
that did not take up the plasmid would die. This method typically generated approximately 
2x104 successfully transformed cells per plate, which equates to approximately 1x105 cfu/ug 
of plasmid DNA.  
3.1.2 pVT100 plasmid retention assay 
Since yeast strains grow much quicker in YEPD rather than SD  -Ura , an experiment was 
performed to test if the strains would maintain pVT100u after a 24 hour growth in YEPD 
media (ie. a non-selective media). Each strain was tested in triplicate. 
Figure 3.1 and Figure 3.2 show the results of the plasmid retention assay. The clear trend 
across all strains is that, for a single 48 hour growth period in a non-selective environment, 
there is no significant loss of pVT100. All strains have over lapping error bars, meaning there 
is no statistically significant difference between the two sample sets. Note that strain 3893 
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Figure 3.1 Set of results for the plasmid retention assay, containing 3 repeats for strain 
3913. The left column is SD media, and acted as a control, whilst the right column is the 
experimental plates, containing no uracil.1000 cells were plated onto each plate (measured 
using a haemocytometer), and If both plates grew similar numbers of colonies, then the 
plasmid would have been retained, allowing the use of YPD as a temporary growth medium. 
The plates above were typical results of the whole experiment. 
 











3.1.3 Domestic strain halo assay 
Once the washed cell method for the halo assays was decided on, rather than the cleared 
media method, the transformed domestic strains were used in the halo assay (see section 2 
for full details) along with BY4742 and Ski4 as positive and negative controls. The graph of 
these results can be found in Figure 3.3. Each experiment was done in triplicate, and error 





Figure 3.2 Plasmid retention assay results; Graph of the data from the colony count (Figure 3.1). 
Data is expressed as the number of separate individual colonies on each plate, averaged across each 
set. Each column is labelled to the corresponding strain name, and error bars shown are +/- 1 
standard deviation, across three repeats. Plasmid is retained in all strains: control and test plates for 
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3.3 Hygromycin B Resistance assays 
Hygromycin B was chosen as a selective marker due to its toxic effect on yeast; Hygromycin 
B binds to the mRNA decoding centre in the small (30S) ribosomal subunit of the 70S 
ribosome. This induces a conformational change which stops bound tRNA from progressing 
from the A binding site to the P site, which leads to a staling of protein synthesis.  
However, there have been examples of yeast displaying hygromycin B resistance. To check 
the resistance of strains used in the current project, a resistance assay was performed. 
Figure 3.4 shows the results of the hygromycin B resistance assay. The outermost column on 
the left and right sides were spotted with 10Pl media containing around 106 cells. Each 
dilution was at 10X meaning that the centre most columns of spots initially contained 103 
cells each. It should be noted that the domesticated strains were not used in this assay; 
disruption of the HO gene common to these strains renders them resistant to the effects of 
Figure 3.3 the results from the halo assay using the domesticated strains, with Ski4 and BY as 
controls. Blue bars represent the untransformed strains and red bars represent the strains 
transformed with pVT100u, expressed as the area of the zone of clearing each strain produced 
after 72hrs incubation. Whilst data for all strains was collected, only Ski4 showed secretion of killer 
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the drug.  All strains grew well on the medium containing 200Pg/ml though there was slight 
variation in growth when 103 were initially put onto the plate. All strains were then plated 
onto the 1000Pg/ml plates. This is where a clear difference emerged, with many strains 
(HN16, HN10, HN1, SX1, BJ20, 21, HN9, HN11, BJ6, and HN15) showing no growth after 72  
hrs.  
Interestingly, some strains showed slight resistance across all concentrations, but still 
showed retarded growth compared to the previous test plate (BT14, FJ7, 99, 60, SX2 SX6 and 
114). Strain BY4742 showed a low level of resistance that was borne out in all 3 repeats, 
each from a different overnight culture, this resistance only showed at the lowest 
hygromycin B concentration (200mg/ml). 







Figure 3.4: Serial dilutions of each untransformed strain plated onto a varying 
concentration of hygromycin B. The concentration of hygromycin B increases down the 
figure: top row; 200Pg/ml, middle row 1000Pg/ml bottom row; 2000Pg/ml. The number of 
cells spotted in each column is labelled at the top, with strain name at the side. The bottom 
left row of each plate is empty. 
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Table 3.1 Summary of hygromycin B resistance assay.  
Strain name 
Highest  concentration to show high growth 
(mg/ml) 
Concentration used for 
transformation selection (mg/ml) 
21 200 1000 
27 200 1000 
BJ20 200 1000 
BJ6 200 1000 
FJ7 200 1000 
HN10 200 1000 
HN11 200 1000 
HN15 200 1000 
HN16 200 1000 
HN2 200 1000 
HN6 200 1000 
HN9 200 1000 
SX1 200 1000 
99 1000 2000 
111 1000 2000 
114 1000 2000 
BT14 1000 2000 
SX2 1000 2000 
SX6 1000 2000 
60 2000 2000 
HN14 2000 2000 
 
3.4 pUKC3564: plasmid construction and yeast transformation 
To insert the KT gene into the wild strains, a plasmid was required that contained both a 
hygromycin B resistance gene and the KT gene. To this end, pUKC3564 was designed and 
created from two existing plasmids; pVT100u and RHx107. 
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3.4.1 Plasmid construction 
To allow plasmid selection in yeast strains without built in auxotrophic mutations, such as 
ůĞƵ ?ȴ0, a plasmid that had an alternative, positive selection marker was required, in this 
case a plasmid which conferred resistance to the drug hygromycin B. It should be noted that 
as part of their modification, strains 3883, 3893, 3903, 3913 and 3923 are resistant to 
hygromycin B, due to the knockout of one allele of the HO gene, full details of which can be 
found in Louvel et al71. This was confirmed by spotting out these strains on agar plates 
containing 2000mg/ml of hygromycin B. 
The strategy used to construct a hygromycin B /Killer Toxin plasmid was to clone the whole  
K1 Killer Toxin gene (an artificial cDNA gene constructed from the RNA virus) from the 
pVT100 plasmid using PCR, and insert the fragment into RHx702, which contained a 
hygromycin B resistance gene (Appendix 1b). The primers for this were positioned so they 
also captured the promoter and terminator. In addition to cloning these genetic elements, 
each primer contained a restriction enzyme site: PciI on the forward primer and XhoI on the 
reverse primer. Both the PCR product and RHx702 were digested overnight with PciI and 
XhoI. When separated on an agaroses gel the digested RHx702 separated into a 6085bp and 
a 2759bp fragment, which was consistent with what would be expected of a successful 
digest with these PciI and XhoI.  




Once the PCR product and RHx702 had been digested, they were ligated using a Roche T4 
DNA Ligase kit (1X reaction buffer, 1:1 approximate molar ratio of gene to plasmid 
(calculated as a 1:1 of weight added in Nano grams/size in bp.  For example 3 fold more 
weight in mass would be required for an insert that is 3 fold smaller than the plasmid), 1ul T4 
ligase left at 20°C for 16hr overnight, Figure 3.5). Product size was checked via gel 
Figure 3.5: Summary Process of creation of pUKC3564. Final plasmid contained both killer toxin 
gene, and hygromycin B resistance. It also contained an ampicillin resistance gene for E.coli 
transformation. First the killer toxin in pVT100u was cloned out using PCR, with the promoter and 
terminators as noted. Then both the base plasmid (RHx702) and the PCR product were digested with 
Pci1 and Xho1in a restriction digest. Then both the vector and insert we ligated together, and the 
final plasmid was bulked up in E.coli. 




yŚŽ ?ĐƵƚƐŝƚĞ WĐŝ ?ĐƵƚƐŝƚĞ 
>ŝŐĂƚŝŽŶ 
ADH1 pro 
K1 Killer toxin ADH1 terminator  
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electrophoresis to confirm successful ligation, before being transformed into super-
competent E. coli for bulking up. A full map of pUKC3564 can be seen in Figure 3.6, which 
includes both the KT gene, and the hygromycin B resistance gene. This map was produced in 
seral cloner by repeating the experiment in-silico. 
 
3.2.2 Transformation of wild strains of yeast 
Once constructed, attempts were made to transform pUKC3564 into all wild strains (see 
section 2.4.1 for methodology).  It was decided to use different levels of hygromycin B for 
different strains, based on the results from the hygromycin B resistance assay (table 3.1) 
Figure 3.6: pUCK3564 plasmid map, labelled with relevant features. Figured produced in Serial 
cloner98 
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 However, after 48 hours, all plates transformed showed either none or very low levels of 
growth (1-2 small colonies). The plates that did show colonies took up to a further 48 hrs 
before the colonies were of a size to be easily picked for growth in liquid media. Many 
strains simply could not be transformed even after a variety of different attempts; selection 
plates showed no growth even after 3 days incubation at 30°C .The lack of transformers was 
seen across multiple repeats, and under different transformation conditions: including using 
longer incubation times (overnight), and longer heat shocks (up to 50 mins). Other 
possibilities are discussed in the discussion and further works section. It would appear that 
this intractability to transformation is a trait inherent to these strains; another lab working in 
parallel with these strains but using different plasmids, have reported the same difficulties72.    
Due to the difficulty in transforming wild strains, only a limited number of strains could be 
transformed with pUCK3564; 8 out of 21 total strains. The successfully transformed strains 
were: HN16, BT14, HN10, HN9, HN6, HN11, BJ6, and HN2 (Table 3.1). Of these only HN6 
showed a similar level of transformants to a BY4742 control, transformed with pUKC3546, 
even then, the number of HN6 cfu was still much lower than BY4742. The other successfully 
transformed strains only showed between 1-15 colonies per plate, over multiple attempts 
3.5 Halo assay for wild strains 
Once the strains transformable with the LiAc method had been identified, they were grown 
in a shaking incubator for 48 hrs, before being diluted down to the same OD600. Each strain 
was then plated in triplicate allowing for statistical significance to be worked out, as well as 
identification of any outliers. To identify any strains that may be native KT producers, all 
untransformed strains were plated out, with a Ski4 positive control. Two strains were 
identified as native KT producers: 60 and NH6. This is summarized in Table 3.3.  Figure 3.7 is 
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an example of a mature halo assay plate: it has been incubated for 3 days, showing good KT 
production for the transformed strains HN6 and HN11, and for the untransformed strain 60. 
However, the transformed strans of BT14, HN16 and HN9 show no KT production, and HN10 
shows only very poor production levels. BY was used as a negative control and Ski4 as a 
positive control. Figure 3.8 is a graph of the data obtained across the 3 repeats of the halo 
assays, with error bars of +/- 1 standard deviation. Table 3.2 contains the average halo size 
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Table 3.2 Average size of halo produced in the halo assay for both the 
untransformed wild type, and the transformed strains.  Strains BT14, NH16, HN9 
and NH2 produced no secretion both when transformed and untransformed so 
have been omitted from this table. 





3903 0 0.788 
3883 0 0.658 
3893 0 0.841 
3923 0 1.046 
3913 0 1.368 
BY 0 1.439 
SKI4 1.367 1.383 
HN6 0.497 1.661 
60 1.167 0 
HN11 0 1.401 
HN10 0 0.124 
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Table 3.3 Summary of successful transformation, and native Killer toxin secreting ability of S. cerevisiae used 
Strain name Successfully Transformed? Native Killer toxin producer? 
21 No No 
27 No No 
60 No Yes 
99 No No 
111 No No 
114 No No 
BJ20 No No 
BJ6 Yes No 
BT14 Yes No 
FJ7 No No 
HN10 Yes No 
HN11 Yes No 
HN14 No No 
HN15 No No 
HN16 Yes No 
HN2 Yes No 
HN6 Yes Yes (very low levels) 
HN9 Yes No 
SX1 No No 
SX2 No No 
SX6 No No 
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Figure 3.7.  An example of a mature halo assay plate. In this case, 2 sets of strains have been tested, 
each in a pair of transformed (on the right of each column) and non-transformed (on the left). The top 
strain in the left hand column is BY4742, whilst the bottom strains in the right hand column are Ski4 
and strain 60 (both untransformed)  





3.6 CRISPR/Cas9 gene insertion 
3.6.1 Selecting the target site for gene insertion 
Running in parallel with the development of pUKC3564 was a set of experiments with the 
aim of inserting the K1 KT gene directly into the genome of the wild yeast strains. To do this 
a target site had to be chosen, which allowed the selection of strains with a successful 
genome integration event. By inserting the gene, as well as a stop codon into the middle of 
the ADE2, which encodes the enzyme Phosphoribosylaminoimidazole carboxylase, any 
Figure 3.8 the results from the halo assay, including the domesticated and wild strains. Blue bars 
represent the untransformed strains and red bars represent transformed strains: pVT100u and 
pUKC3564 for the domesticated strains and the wild strains respectively. Strains BT14, NH16, HN9 
and NH2 produced no secretion both when transformed and untransformed so have been omitted 
from this graph. Strain 60 was not transformed, and so there is no data for transformed strain 60, 
this does not mean it would not secrete, but the data was not obtained. Strains BY and Ski4 are 
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strains with a successful genome integration event would accumulate adenine precursors, 
which colour the cell a characteristic red. To check conservation of the chosen target site 
within the genome, BLAST73 was used on the target sequence, against 50 S. cerevisiae 
reference genomes found on the Saccharomyces Genome Database74 ( Appendix 2).The 
target sequences were completely conserved between all the genomes tested.  Using this 
sequence would also produce no off target cuts. 
Once the target was decided, the sgRNA was designed and inserted into pML107 (section 
2.4.4). PCR was performed as per section 2.4.4, and both the repair template and pML107 
were transformed into the target strains.  This was attempted 4 times, however, no red 
colonies were seen, and due to time pressure, it was decided that proceeding on the 
pUKC3564 front was more likely to produce results. 
3.7 Secretome analysis 
An alternative method to evaluate the proteins being secreted by a test strain was to 
precipitate the proteins found in the secretome, and visualises them on an SDS tris-tricine 
gel. This would allow basic identification of any products, and complement the data 
obtained from the halo assay. Given time, it could lead on to further analysis such as mass 
spectrometry .To this end, the secretome analysis was this was performed in parallel with 
the halo assay. To evaluate the secretome of the strains a protein precipitation approach 
was taken. Cells were grown overnight in YPD media, before the spent media was cleared of 
cells via centrifugation. Two approaches were tried to isolate secreted proteins from the 
medium: TCA protein precipitation, and Strataclean protein binding beads. Both methods 
ended with the samples being boiled in SDS sample buffer, before being loaded onto a tris-
tricine gel, and then stained with commassie brilliant blue. Figure 3.9 is the gel for 
Ski4/BY4742, using both methods of protein precipatation.   Figuere 3.10 shows the tris-
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tricine SDS PAGE gel, both of the secreated proteins, and the cellular proteins, released by 
















Figure 3.9 TCA / Strataclean bead gel stain with coomassie blue. Lane M: maker, 
PageRuler plus. Lane B: BY4742 media. LaneS4: Ski4 media. Size of marker bands noted in 
killer Dalton. Note the band at 15kDa; this is likely the killer toxin as previous work on KT 
has noted that it appears at a lower weight marker than expected, at around 15 kDa. 
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Figure 3.10 TCA protein precipitation tris-tricine gel stain with coomassie blue. Top 
panel; cellular proteins from lysed cells. Bottom panel; cell cleared media. Each lane is 
marked with the name of the strain run in that lane. The lanes marked M are the marker 
lanes.Ski4 and By4742 are controls. Unlike figure 3.8, neither gel shows killer toxin 
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3.8 Gaussia luciferase assay 
As well as the K1 Killer toxin, another protein was used as a secondary model protein; 
Gaussia luciferase (GL) , a secreted luciferase which uses coelenterazine as a substrate to 
produce light at 482 nm. For this assay, the 5 domestic strains as well as BY4742 were 
transformed with pCG495, a  
GL containing plasmid, and tested with an untransformed BY4742 as a control (Section 
2.5.2).  This assay had measurements taken at 15, 30 and 45 minute intervals, Figure 3.11 is 
the graph of these sets of measurements. We can see that the control strain (BY) 
transformed with the plasmid out performs all the domestic strain, which is consistent with 
Figure 3.11 Graph of the GL data. The data is the average of 6 measurements for each strain, and 
readings were taken every 15 min, after 10 min incubation, as per the protocol of the kit used.  
Each strain is demarked by a different coloured line. Both blank, and a BY negative control are 
shown along the bottom, showing that all strain outperformed a control. 
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the halo assay results, however, this is where the similarities end: strain 3883 had shown a 
very low KT production, but was the second heist in this assay. This might indicate that each 
strain is better a particular set of proteins, and if this assay was generalised to all the strains, 
we might see a similar difference in results. 
4. Discussion and future work 
4.1 strategies for genetically engineering yeasts 
During this project, a number of different methods have been used to insert the killer toxin 
ŐĞŶĞƚŝĐŝŶĨŽƌŵĂƚŝŽŶ ?dŚŝƐ ‘ŐĞŶĞ ?ŝƐĂŶĂƌƚŝĨŝĐŝĂůĐƌĞĂƚŝŽŶŽƌŝŐŝŶĂůůǇŽĨĐEĐƌĞĂƚĞĚĨƌŽŵƚŚĞ
killer toxin viral dsRNA particle. For sake of ease, in this document, the term killer toxin gene 
is used to refer to this DNA which encode the toxin, as well as the promoter and terminator 
used (ADH1 in this case). 
4.1.1 LiAc transformations 
Transforming the domesticated strains and BY4742 with pVT100u, pML107 and pCG495, was 
done without any problems. However, using the wild strains proved more problematic. The 
exact reason for this is unclear, however it is interesting to note, that of the 8 strains 
successful transformed, (NH16, BT14, NH10, HN9, HN6, HN11, BJ6 and HN2) all but one 
(BT14) came from china, and all bar BT14 and BJ6 came from bark of fagaceae trees in 
Hainan.  
The yeast cell wall is extremely tough, comprising of cross linked layered branched mannose, 
Beta glycans, and chitin; yeasts also show the ability to changes its cells wall structure in 
response to environmental stresses75. As a direct result, getting DNA into a yeast cell is 
difficult, and requires the use of 30 minutes heat shock, as well as high concentrations of 
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lithium acetate. whilst the exact underlying molecular mechanism though which lithium 
acetate transformations function is unclear, some recent studies have looked at the 
structural processes that occur during transformation 76. Polyethylene glycol (PEG) allows 
DNA to adhere to the cell walls, whilst lithium acetate and heat shock serve to help increase 
the permeability of the cell wall. This was shown with experimentation with transformation 
of spheroplasts (which lack a wall); this process was unaffected by the presents of lithium 
acetate, or by heat shock of the sample77,78. 
It is possible that the strains resistance to transformation either have fundamental 
differences in the nature of their cell walls (such as in the complexity of branched mannose) 
or a greater ability to adapt to a hostile environment (such as heat shock). Such adaptations 
might be serve as a direct resistance to foreign DNA; it has been theorised that one of the 
key roles of the cell wall in yeasts is as a protective measure against viral infection79, which 
would certainly include a resistance to picking up large amounts of intact DNA from the 
environment. Alternatively, such resistance could simply be a side effect of environmental 
adaptation; for example, resistance to heat shock. This could be an interesting avenue of 
investigation: a range of phenotypic assays (heat shocks, extremes of PH or osmotic stress 
etc.) could help point to an underlying advantage which may explain this resistance to 
transformation.  
4.1.2 CRISPR 
The aim of the CRISPR experiment was to insert the KT gene into the genome of the test 
strain, allowing stable insertions without the worry of plasmid loss. Developing the plasmid 
required would also mean that genes for any test recombinant protein could be quickly 
inserted into the genome, by simply chaining the repair template. Overall, the CRISPR 
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experiment was not successful, this project has laid the ground work for future projects 
involving CRISPR mediated gene insertion in the yeast genome: the killer toxin gene was 
successfully inserted into pML107, along with the guide RNA to target the system to the 
ADE2 gene. One possibility for the unsuccessful outcome of this experiment is the length of 
the insert: much of the previous work done using Cas9/CRISPR, has focused on single base 
pair, site directed mutagenesis, or small (<100bp) insertions and deletions. Larger insertions 
have only recently been explored 80. The method used here had followed the methodologies 
for small inserts, and would require modification to accommodate the larger 3kB insert 
required, most notably the use of homologous arms, much larger than were used for this 
project (around 10 fold longer ). 
4.1.3 Future work 
Given more time on this project, development of the CRISPR/Cas9 technology would take 
ƉƌŝŽƌŝƚǇ PƐƚĂďůĞŝŶƚƌŽĚƵĐƚŝŽŶŽĨƚŚĞ<d ‘ŐĞŶĞ ? ?ŝŶƚŽƚŚĞŐĞŶŽŵĞ ?ǁŽƵůĚĚŝƐƉĞŶƐĞǁŝƚŚƚŚĞ
requirement of markers such as hygromycin B resistance.  Using larger homologous arms for 
homologues recombination may yield results: the Zhang lab has reported insertions of up to 
5.3 kB with A 720bp right arm and 967bp left arm80. 
If the CRISPR/Cas9 approach cannot be successfully utilised, then I would proceed on the 
plasmid front. To overcome the transformation difficulties, I would use a single plasmid-
multiple proteins approach: By using pUKC3564 as a starting point, multiple recombinant 
proteins could be inserted into the same plasmid, thus allowing for multiple secretion assays 
ŽĨĨĂƐŝŶŐůĞƚƌĂŶƐĨŽƌŵĂƚŝŽŶ ?tŚŝůƐƚƚŚŝƐĚŽĞƐŶ ?ƚĂĚĚƌĞƐƐƚŚĞƐƚƌĂŝŶƐƚŚĂƚŚĂǀĞǇĞƚƚŽ
transformed at all, it would save large amounts of time and resources that would otherwise 
be taken up with repeated transformation attempts. 
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 To tackle the transformation issue, transforming spheroplasts via electroporation would be 
a way to get around any problems that may be caused by the cell wall: if this method was 
successful, it would confirm that it is the cell wall that causes the resistance to 
transformation seen. Spheroplasts would be generated using lyticase treatment, to break 
down the cell wall. 
To analyse the underlying causes of the transformation problems, looking at the cell wall 
may yield useful results; previous yeast cell wall studies have utilised High pressure freezing 
Transmission electron microscopy (HPF-TEM) to look at size and structure of the yeast cell 
wall81 ?/ƚŵŝŐŚƚďĞƉŽƐƐŝďůĞƚŽƐĞĞĚŝĨĨĞƌĞŶĐĞďĞƚǁĞĞŶƚŚĞƐĞƐ ‘ƵŶƚƌĂŶƐĨŽƌŵĂďůĞ ?ƐƚƌĂŝŶƐ ?ĂŶĚ
wild type strains, which may reveal more about how the LiAc transformation exactly works. 
4.2 Native Killer toxin in Wild strains  
During the course of this investigation, a number of strains generated positive results from 
the halo assay without being transformed with a KT producing plasmid. This indicates they 
are native producers of KT; growing these strains on a lawn of S6 strain leads to a halo of 
killed cells. 
4.2.1 Producing strains 
The vast majority of wild yeast strain do not produce killer toxin. For reasons discussed 
below, it can be a disadvantage to host the virus. The Ski mutants (Ski4 being a member) are 
notable exceptions to this, as not only are they natural secretors, but also contain mutations 
 ?ŝŶƚŚĞƐŽĐĂůůĞĚ ‘^ŬŝŐĞŶĞƐ ? ?ǁŚŝĐŚŵĂŬĞƐƚŚĞŵ ‘ƐƵƉĞƌƉƌŽĚƵĐĞƌƐ ? ?dŚŝƐŵĂŬĞƐ^Ŭŝ ?ĂŐŽŽĚ
benchmark against which to test the secreting strains.  By using the halo assay, and 
measuring the size of the zones of clearing, we can get an idea of the strains relative abilities 
to secrete KT, and so infer there overall secretion abilities. 
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 Of the wild strains, two were noted as generating positive results in the halo assay, implying 
they are producers of killer toxin, even when untransformed:  60 and HN6.  Strain 60 was the 
most potent producer, almost at the level of Ski4, whereas HN6 produced significantly less. 
This small number is consistent with previous studies , which find very low occurrence of KT 
production in wild strains 82, 83. This raises the question of why these strains might be natural 
producers; producing KT can be a selective advantage, by killing off other strains competing 
for the same ecological niche. However, the KT virus does come with disadvantages; the fact 
that natural the gene is encoded on a dsRNA virus means the cell hosting it must give up any 
RNA silencing capacity. If a cell within a carrier colony develops this ability, it will lose the 
immunity granted by the dsDNA virus, and be killed by its secreting neighbours meaning that 
once infected, the strain self-selects for the virus84. Of course this also mean infection with 
the KT virus renders the strain, and any descendants, vulnerable to attack from other 
viruses, due to the removal of the RNAi systems. The end result is that strains that acquire 
the KT virus do have an advantage over other, sensitive strains, but give up a measure of 
their ability to defend themselves. It has been suggested that this trade is somewhat 
unfavourable, and that this might explain the low numbers of wild strain hosts84 . 
The fact that the two different strains appear to produce different levels of killer toxin could 
indicate their secretion abilities vary; strain 60 being far more efficient than NH10. 
Alternatively, they could be producing different forms of KT: there are 2 common variants of 
killer toxin, K1 and K28. It is possible that S6 is more sensitive to one variant than the other 
4.2.2 Future work 
 
It is very possible that these strains are not producing KT, but rather another protein that is 
toxic to S6. Given more time I would perform the same TCA protein precipitation that was 
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performed on the domesticated strains, to check if these strains were producing KT. 
Extracting all the dsRNA from each strains would also elucidate what, if any, dsRNA viruses 
infect these two strains. 
This would also help clear up if the two strains are infected with different viruses and so are 
producing different toxins.  This would also neatly segue into creating different plasmids 
with the different killer toxin to assay which one is more efficient at killing a variety of 
sensitive strains.     
4.3 The gaussia luciferase secretion assay in the domestic strains 
4.3.1 Assay results 
The results of the gaussia luciferase assay show the domestic strains tested secreting a very 
low level of GL, which was borne out over both experiments. This is largely consistent with 
the work of the halo assay for KT; the domestic strains do not secrete proteins as well as 
BY4742. There is however one difference: the halo assay showed that 3813 secreted K1 KT at 
a similar level to BY4742, but  3813 produced an average of only 128 fluoresces units at 
T=45, almost 4 fold lower than BY4742 at the same time point. 
4.3.2 Future work  
The difference between the GL assay and the halo assay, when looking at strain 3913, 
highlights the importance of using different proteins; GL  is much larger than KT and has 
more disulphide bounds, indicated that 3913 is better as secreting more simple proteins, but 
this ability is significantly less with larger, more complex proteins. 
Inserting the GL gene into the wild strains,  may show different strains having different 
abilities to secrete GL in comparison to K1 KT. If a fast and simple method could be 
developed for gene insertion, then a range of proteins of different size and complexities 
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containing different PTM, could be used to assay the full range of the wild strains abilities to 
secret recombinant proteins. 
4.4 Protein secretion in yeasts 
4.4.1 The dangers of ROS 
Whilst this project has largely focused on using killer toxin as a model protein, we also have 
to look at the greater context, of general recombinant protein production.  When thinking 
about protein secretion in yeasts, we have to consider how our product of interest affects 
and are affected by other process in the cell. On the most basic level, this might include 
looking at the toxicity of the product itself to the cell. We should also consider if the product 
or the process of making the product puts stress on the cell, which we must take into 
consideration when growing these cells for example the generation of reactive oxygen 
species by the production of disulphide containing proteins.  
It has been well established that Reactive oxygen species (ROS) and cell apoptosis are 
linked85,86,87 .in fact the mechanism of action for KT seems to involve ROS generation88. 
Molecular oxygen  Is the terminal electron acceptor during the formation of disulphide 
bounds, though the action of Ero1 and PDI which in turn leads to the generation of peroxide, 
a strong ROS. This means that cells which produce large amounts of disulphide bound 
containing proteins, necessarily would have to deal with large volumes of ROS, and so the 
cell is limited in the volume it can produce by its ROS clearance mechanisms89 (such as 
peroxidases).Normally this would not be a problem, however, by introducing a gene with a 
highly active promoter, the cells  have a greater level of ROS to deal with.  These cells are 
also more vulnerable to other sources of ROS, including exogenous ROS, and to any 
spontaneous mutations which affect the ROS system, directly or indirectly.  
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Chronic reductive stress manifests in the ER as futile cycles of proteins with disulphide bonds 
folding, when bound to chaperone proteins and members of the PDI protein family, and 
unfolding, as they are released. Not only do these cycles waste the cells resources, they also 
produce more ROS with each cycle. Cells that are producing large volumes of these proteins 
ĂƌĞŵŽƌĞŐƌĞĂƚůǇĂĨĨĞĐƚĞĚ PŵŽƌĞƉƌŽƚĞŝŶƐƵŶĚĞƌŐŽŝŶŐƚŚĞƐĞĐǇĐůĞƐ ?ŵĞĂŶƐŵŽƌĞZK^
produced.  
Hydrogen Peroxide also has a direct effect on the endoplasmic reticulum ability to fold 
proteins, by causing down regulation of the foldase GRP94 and GRP7890,91. It has been 
suggested that CYP2E1- derived oxidant stress was responsible for this down regulation92, 
thought the exact mechanism is still unclear. 
All these problems caused by ROS mean that there is a hard limit on protein production, 
which is related to the cells ability to deal with ROS, specifically peroxide. Due to the fact 
that many peroxidases are limited by the rate of diffusion 93 attempts to optimise their 
structure to increases the rate of catalysis would be fruitless. Instead to increases the 
production levels of disulphide bond containing proteins, work could be done to increase 
protein levels of these enzymes, for example. Looking at human cell which produce a large 
volume of disulphide containing proteins, such as plasma cells, may hold the key to this.  By 
increasing a cells resistance to acute oxidative stress, we can increase the upper limit of 
production of our protein of interest. Yeast cells only have the Ero1-PDI pathway to produce 
disulphide bounds94, and as a result an increases in disulphide bounds always leads to an 
increase in hydrogen peroxide formation. Mammals on the other hand contain tissue 
specific alternative pathways , such as the Ero194and PRDX4 mediated95 amongst others96, 
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Figure 4.1, some of which uses hydrogen peroxide as the terminal electron acceptor, others 





It should also be noted that very few proteins are natively secreted by yeasts: in fact killer 
toxin is the only endogenous disulphide bound containing protein secreted by S .cerevisiae. 
The dangers of producing high levels of peroxide do not often counter balance the 
advantages brought by secreted proteins, as a result, infection by the KT virus is rarely see, 
and is defended against by native RNAi. KT may not be an exception to this rule, as we have 
Figure 4.1 Summary of various disulphide bound forming pathways in mammalian cells. 
With the exception of the Ero1 pathway, these methods are unavailable to yeast cells, 
which must produces peroxide to create disulphide bounds. Taken from N. J. Bulleid and 
L. Ellgaard 201196 
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already discussed, there are other selection pressure selecting for the dsRNA virus than just 
environmental fitness. 
4.4.2 Protein precipitation; secretome and cellular protein analysis 
In an attempt to evaluate the secretome of the domestic strains, two methodologies were 
used: Trichloroacetic acid (TCA) protein precipitation and Strataclean beads precipitation 
both methodologies seem to work for the precipitation of killer toxin from the secretome, 
with clear bands. TCA precipitates less material , which should not have been much of a 
problem however, when the TCA precipitation was repeated, it did not produce substantial 
results, even with longer incubation times. The higher sensitivity of the bead should produce 
more clear results and would allow more strains to be evaluated. This is likely down to the 
low levels of KT secreted natively by cells, as the cellular proteins gel shows a very strong 
signal which is consistent with the large amounts of total protein seen inside of the cell.  
The next stage would be to use mass spectrometry to confirm the identity of the protein 
band. If this was the case, then using the Strataclean beads, and band intensity analysis 
could be a powerful quantitative alternative to the halo assay for killer toxin. 
4.5 hygromycin B resistance in the wild strains 
 
It is worth briefly looking at the very high level of resistance displayed by the wild strains, to 
the anti-biotic hygromycin B; such high resistance is unusual in wild strains of S.cerevisiae. 
This is especially notice able at levels 10 fold more than what is typically required to inhibit 
growth (2000Pg/ml required, whereas 200Pg/ml is more typical in ws), where two strains; 
60 and HN14 showed a single colony each. This was repeated 3 times, with single colonies 
developing on two of the repeats .This effect has been seen before in Monilinia fructicola, 97 
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but little work has been done in S.cerevisiae. The mutants seen in M. fructicola showed 
reduced growth rate and reduced resistance to demethylation, but the underlying mutation 
was not elucidated.  Testing these strains to find out the underlying causes, by using SNP 
arrays, and testing to see if the strains can adapt to any other anti-biotics, would be 
worthwhile, to see if these strains are more adaptable than other strains. 
4.6 Wild strains as protein production and secretion 
The main aim of this project was to test the viability of these strains as good producers of 
recombinant protein production, so the advantages and disadvantages should be looked at. 
4.6.1 The advantages of using the wild strains tested here  
Despite some resistance, it has been shown that at higher concentration levels of 
hygromycin B is a useable selective marker for plasmid selection, allowing plasmids to be 
easily designed to insert recombinant protein genes, or use CRISPR/Cas9 for further 
engineering. 
Strain 60 and HN6 both showed they natively produce killer toxin, and so have the required 
machinery to produce correctly folded disulphide bound containing proteins; strain 60 had a 
halo area of 1.16 cm2 when untransformed, larger than 4 of the domesticated strains.HN6 
produced only 0.496 cm2, far less than any of the transformed strains , however, when 
transformed this level was greatly increased to 1.66 cm2 , implying the lower secretion rate 
is linked to the dsRNA KT virus itself (transcription speed for example), not the overall 
machinery of the strain .  
Strains HN6, and HN11 showed that once transformed with pUCK3564 they could produce 
large volumes of killer toxin, rivalling even Ski4. Transformed Ski4 produced an average halo 
of 1.38 cm2, whereas HN6 and HN11 produced 1.66 cm2 and 1.40cm2. Adding in error bars of 
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+- 1 standard deviation, HN11 and SKI4 become similar, but HN6 remains a larger secretor 
with a lower bound of 1.58 cm2, compared to the upper bound of ski4 of 1.44 cm2. 
Interestingly untransformed strain 60 has an average halo of 1.16 cm2, which is only 0.20 
cm2 ƐŵĂůůĞƌƚŚĂŶƵŶƚƌĂŶƐĨŽƌŵĞĚƐŬŝ ? ?ƚŚĞƐŽĐĂůůĞĚ ‘ƐƵƉĞƌƉƌŽĚƵĐĞƌ ? ?ŝŶĚŝĐĂƚŝŶŐƚŚĂƚƐƚƌĂŝŶ ? ?
might have one of the Ski mutations. 
 Strains HN6 and HN11 would be the perfect candidates to take forwards for further testing. 
HN6 is of particular interest, as it showed a good level of transformation, though still less 
than BY4742 transformed under the same condition, whilst HN6 produced the largest halo of 
all strains tested . 
4.6.2 The disadvantages of using the wild strains tested here 
A massive hurdle to use of theses strains is the resistance to standard LiAc transformation. 
Only 9 of  the 21 strains were not resistant, and those that were successfully transformed 
showed very low efficiency. Until alternative methodologies have been tried (transformation 
of spheroplasts via electroporation for example76), these strain cannot be tested for 
recombinant protein secretion. 
Of the ten strains successfully transformed, only four gave observable evidence of secretion 
and of those (HN10) showed an extremely low level of secretion in the halo assay: around 
9% of the level seen with Ski4. The five remaining strains (HN9, BJ6, HN16,BT14 and HN2) as 
well as HN10, have displayed limited or no ability to secrete killer toxin, so would be 
inappropriate to use in recombinant protein production. 
Of course, until these strains have their genomes published, we are also unable to perform 
any analysis on any genetic variation showed by these strain: even if a massively successful 
secretor was found. Whilst these strains could be used without the need for genetic analysis, 
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if the underlying genetic variance responsible for the observed phenotype was known, it 
ĐŽƵůĚďĞŝŶƚƌŽĚƵĐĞĚŝŶƚŽĞǆŝƐƚŝŶŐŚŝŐŚƉƌŽĚƵĐŝŶŐƐƚƌĂŝŶƐ ?ƚŽĞŶŚĂŶĐĞƚŚĞƐĞŝŶĚƵƐƚƌŝĂůƐƚƌĂŝŶƐ ?
protein production rate. 
4.6.3 The overall view of the wild strain and summary of the project 
Of the above disadvantages, two of them may be able to be overcome: genome sequencing 
technology is getting faster and cheaper year on year, meaning these strain could easily be 
fully sequenced, or if full sequencing was still too expensive, SNP arrays could be used to 
elucidate genetic variance in successful secretor, which could be used to explain the 
observed phenotype. As mentioned above, alternative transformation strategies may yield 
good results. 
The simple fact that BT14 HN16, HN9 BJ6 and HN2 generated no secretion in the halo assay, 
and that HN10 secreted very little, means these strains are not useful to us. However strain 
60, HN6, HN2 and HN11 show very good secretion, so could be carried forward for further 
testing (figure 3.2). 
So to summaries, whilst many of the strain tested here proved to be either resistant to 
transformation, or produced no or little killer toxin when transformed, four of the tested 
trains showed good secretion. This shows that there is potential in testing a wide variety of 
wild strain. The ƐŝŵƉůĞĨĂĐƚŝƐǁĞĚŽŶ ?ƚŬŶŽǁǁŚĂƚƉŽƚĞntially useful strain we might find, 
when testing wild strains. 
During this project, a plasmid based method was developed to insert the killer toxin gene 
into strains lack auxotrophic makers, as well as a method to assay for secreted killer toxin, 
namely the halo assay.  The secretome was also looked at, and, using the strataclean beads, 
killer toxin extracted from media that had been used to grown transformed strains. There is 
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plenty of future work possible from this project, such as confirming the identity of the killer 
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Appendix 1: Plasmid maps 
Plasmid maps: plasmid maps for all plasmids used. A) pUKC3564; novel Killer toxin and 
hygromycin B resistance plasmid, B) RHx702; original hygromycin B resistance plasmid, C) 
pVT100; original Killer toxin, D) pML107; Cas9/Guide RNA combined CRISPR plasmid. E) 
pCG495; Gaussia luciferase containing plasmid 
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Appendix 2: CRISPR Blast results 
Blast results across 58 model strains of yeast. Sequence used: 
TTTTCCCGGTTGTGGTATATTTGGTGTGGAAATG which is the target sequence with 4 residues 
either side 
 




gb|AFDF01001248.1| Saccharomyces cerevisiae 
T73 Contig159.9, whole genome sh... 
49.4 3.10E-
06 
gb|AFDG01001124.1| Saccharomyces cerevisiae 
CLIB382 Contig348.8, whole genom... 
49.4 3.40E-
06 
gb|ABPD01002640.1| Saccharomyces cerevisiae 




gb|AEWM01001999.1| Saccharomyces cerevisiae 




gb|AEWO01002210.1| Saccharomyces cerevisiae 




gb|AFDD01000257.1| Saccharomyces cerevisiae 




gb|ABPC01001609.1| Saccharomyces cerevisiae 




gb|ABSV01002165.1| Saccharomyces cerevisiae 




gb|AFDC01001012.1| Saccharomyces cerevisiae 




gb|AEWP01000422.1| Saccharomyces cerevisiae 




gb|AGSJ01000028.1| Saccharomyces cerevisiae 




gb|AEWL01000738.1| Saccharomyces cerevisiae 




gb|AEWN01000414.1| Saccharomyces cerevisiae 




gb|JRIG01000347.1| Saccharomyces cerevisiae 




gb|JRIE01000280.1| Saccharomyces cerevisiae 




gb|JRIM01000838.1| Saccharomyces cerevisiae 




gb|JRIK01000125.1| Saccharomyces cerevisiae 
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gb|JRIJ01000006.1| Saccharomyces cerevisiae 




gb|JRII01000136.1| Saccharomyces cerevisiae 




gb|JRIH01000113.1| Saccharomyces cerevisiae 




gb|JRIB01000237.1| Saccharomyces cerevisiae 




gb|JRIC01000085.1| Saccharomyces cerevisiae 




gb|JRIF01000155.1| Saccharomyces cerevisiae 




gb|JRID01000339.1| Saccharomyces cerevisiae 




dbj|BABQ01000174.1| Saccharomyces cerevisiae 




gb|AEHG01000400.1| Saccharomyces cerevisiae 




gb|JRIU01000141.1| Saccharomyces cerevisiae 




gb|JRIO01000092.1| Saccharomyces cerevisiae 




gb|ACFL01000063.1| Saccharomyces cerevisiae 




gb|JRIV01000149.1| Saccharomyces cerevisiae 




gb|JRIW01000060.1| Saccharomyces cerevisiae 




gb|ADXC01000074.1| Saccharomyces cerevisiae 




gb|JRIY01000194.1| Saccharomyces cerevisiae 




gb|JRIZ01000031.1| Saccharomyces cerevisiae 




gb|JRIR01000197.1| Saccharomyces cerevisiae 




gb|JRIX01000100.1| Saccharomyces cerevisiae 




gb|JRIL01000028.1| Saccharomyces cerevisiae 




gb|ADVV01000079.1| Saccharomyces cerevisiae 
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gb|AAEG01000058.1| Saccharomyces cerevisiae 




gb|ADVS01000045.1| Saccharomyces cerevisiae 









gb|JRIS01000158.1| Saccharomyces cerevisiae 




gb|JRIQ01000023.1| Saccharomyces cerevisiae 




gb|JRIN01000192.1| Saccharomyces cerevisiae 




gb|AFDE01000030.1| Saccharomyces cerevisiae 




gb|AEHH01000073.1| Saccharomyces cerevisiae 




gb|JRIP01000004.1| Saccharomyces cerevisiae 




gb|JRIT01000140.1| Saccharomyces cerevisiae 




gb|ACVY01000004.1| Saccharomyces cerevisiae 




gb|AEJS01000062.1| Saccharomyces cerevisiae 




gb|AEEZ01000095.1| Saccharomyces cerevisiae 




gb|AAFW02000030.1| Saccharomyces cerevisiae 




gb|AMDD01000032.1| Saccharomyces cerevisiae 



















emb|FN394216.1| Saccharomyces cerevisiae 












1. Ferrer-Miralles, N., Domingo-Espín, J., Corchero, J. L., Vázquez, E. & Villaverde, A. 
Microbial factories for recombinant pharmaceuticals. Microb. Cell Fact. 8, 17 (2009). 
2. Li, R., Chen, Q., Wang, P. G. & Qi, Q. A novel-designed Escherichia coli for the 
production of various polyhydroxyalkanoates from inexpensive substrate mixture. 
Appl. Microbiol. Biotechnol. 75, 1103 W1109 (2007). 
3. Weickert, M., Doherty, D., Elaine, B. & Peter, O. Optimization of heterologous protein 
production in Escherichia coli. Curr. Opin. Biotechnol. 7, 494 W499 (1996). 
4. Widmann, M. Comparison of folding rates of homologous prokaryotic and eukaryotic 
proteins. J. Biol. Chem. 275, 18619 W18622 (2000). 
5. Hershberg, R. & Petrov, D. A. Selection on codon bias. Annu. Rev. Genet. 42, 287 W299 
(2008). 
6. Novy, R., Drott, D., Yaeger, K. & Mierendorf, R. Overcoming the codon bais of E. coli 
for enhanced protein expression. Innovations 4 W6 (2001). doi:10.2144/000114256 
7. Kurland, C. & Gallant, J. Errors of heterologous protein expression. Curr. Opin. 
Biotechnol. 7, 489 W493 (1996). 
8. Gustafsson, C., Govindarajan, S. & Minshull, J. Codon bias and heterologous protein 
expression. Trends Biotechnol. 22, 346 W353 (2004). 
9. Devi, N., Adivitiya & Khasa, Y. P. A combinatorial approach of N-terminus blocking and 
codon optimization strategies to enhance the soluble expression of recombinant hIL-7 
in E. coli fed-batch culture. Appl. Microbiol. Biotechnol. (2016). doi:10.1007/s00253-
016-7683-5 
10. Snajder, M., Mihelic, M., Turk, D. & Ulrih, N. P. Codon optimisation is key for pernisine 
expression in Escherichia coli. PLoS One 10, 1 W16 (2015). 
11. Wiedemann, B. & Boles, E. Codon-optimized bacterial genes improve L-arabinose 
fermentation in recombinant Saccharomyces cerevisiae. Appl. Environ. Microbiol. 74, 
2043 W2050 (2008). 
12. Baneyx, F. & Mujacic, M. Recombinant protein folding and misfolding in Escherichia 
coli. Nat. Biotechnol. 22, 1399 W1408 (2004). 
13. Williams, D. C., Frank, R. M. Van, Muth, W. L. & Burnett, J. P. Cytoplasmic inclusion 
bodies in Escherichia coli producing biosynthetic human insulin proteins. 215, 687 W
689 (2016). 
14. Singh, A., Upadhyay, V., Upadhyay, A. K., Singh, S. M. & Panda, A. K. Protein recovery 
from inclusion bodies of Escherichia coli using mild solubilization process. Microb. Cell 
Fact. 14, 41 (2015). 
15. Agarwal, S., Singh, R., Sanyal, I. & Amla, D. V. Expression of modified gene encoding 
ĨƵŶĐƚŝŽŶĂůŚƵŵĂŶɲ-1-antitrypsin protein in transgenic tomato plants. Transgenic Res. 
17, 881 W896 (2008). 
87 | P a g e  
 
16. Coloma, M. J., Clift, A., Wims, L. & Morrison, S. L. The role of carbohydrate in the 
assembly and function of polymeric IgG. Mol. Immunol. 37, 1081 W1090 (2001). 
17. Gerngross, T. U. Advances in the production of human therapeutic proteins in yeasts 
and filamentous fungi. Nat. Biotechnol. 22, 1409 W1414 (2004). 
18. Kim, J. Y., Kim, Y. G. & Lee, G. M. CHO cells in biotechnology for production of 
recombinant proteins: current state and further potential. Appl. Microbiol. Biotechnol. 
93, 917 W930 (2012). 
19. Walsh, G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32, 992 W1000 (2014). 
20. Maccani, A. et al. Pichia pastoris secretes recombinant proteins less efficiently than 
Chinese hamster ovary cells but allows higher space-time yields for less complex 
proteins. Biotechnol. J. 9, 526 W537 (2014). 
21. Demain, A. L. & Vaishnav, P. Production of recombinant proteins by microbes and 
higher organisms. Biotechnol. Adv. 27, 297 W306 (2009). 
22. Liu, Z., Keith, E. J. T., José L., M., Petranovic, D. & Jens, N. Different expression systems 
for production of recombinant proteins in Saccharomyces cerevisiae. Biotechnol. 
Bioeng. 109, 1259 W1268 (2012). 
23. Rosano, G. L. & Ceccarelli, E. a. Recombinant protein expression in Escherichia coli: 
advances and challenges. Front. Microbiol. 5, 1 W17 (2014). 
24. Idiris, A., Tohda, H., Kumagai, H. & Takegawa, K. Engineering of protein secretion in 
yeast: strategies and impact on protein production. Appl. Microbiol. Biotechnol. 86, 
403 W417 (2010). 
25. Macek, B. et al. Phosphoproteome analysis of E. coli reveals evolutionary conservation 
of bacterial Ser/Thr/Tyr phosphorylation. Mol. Cell. Proteomics 7, 299 W307 (2007). 
26. Sahdev, S., Khattar, S. K. & Saini, K. S. Production of active eukaryotic proteins through 
bacterial expression systems: a review of the existing biotechnology strategies. Mol. 
Cell. Biochem. 307, 249 W264 (2007). 
27. Amano, K. et al. Engineering of mucin-type human glycoproteins in yeast cells. Proc. 
Natl. Acad. Sci. U. S. A. 105, 3232 W7 (2008). 
28. Gerngross, T. U. Advances in the production of human therapeutic proteins in yeasts 
and filamentous fungi. Nat. Biotechnol. 22, 1409 W1414 (2004). 
29. Hamilton, S. R. & Gerngross, T. U. Glycosylation engineering in yeast: the advent of 
fully humanized yeast. Curr. Opin. Biotechnol. 18, 387 W392 (2007). 
30. Fischer, R., Twyman, R. M. & Schillberg, S. Production of antibodies in plants and their 
use for global health. Vaccine 21, 820 W825 (2003). 
31. Pollock, D. P. et al. Transgenic milk as a method for the production of recombinant 
antibodies. J. Immunol. Methods 231, 147 W157 (1999). 
32. Barnard, G. C. et al. High-throughput screening and selection of yeast cell lines 
expressing monoclonal antibodies. J. Ind. Microbiol. Biotechnol. 37, 961 W971 (2010). 
88 | P a g e  
 
33. Durocher, Y. & Butler, M. Expression systems for therapeutic glycoprotein production. 
Curr. Opin. Biotechnol. 20, 700 W707 (2009). 
34. Cregg, J. M., Barringer, K. J., Hessler,  a Y. & Madden, K. R. Pichia pastoris as a host 
system for transformations. Mol. Cell. Biol. 5, 3376 W85 (1985). 
35. Lin-Cereghino, J., Cregg, J. M., Cereghino, J. L. & Cregg, J. M. Heterologous protein 
expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 24, 45 W
66 (2000). 
36. Giga-Hama, Y. et al. High Wlevel expression of human lipocortin I in the fission yeast 
Schizosaccharomyces pombe using a novel expression vector. Bio/Technology 12, 
400 W404 (1994). 
37. Agaphonov, M. O., Beburov MYu, Ter-Avanesyan, M. D. & Smirnov, V. N. A disruption-
replacement approach for the targeted integration of foreign genes in Hansenula 
polymorpha. Yeast 11, 1241 W7 (1995). 
38. Sakai, Y., Akiyama, M., Kondoh, H., Shibano, Y. & Kato, N. High-level secretion of 
fungal glucoamylase using the Candida boidinii gene expression system. Biochim. 
Biophys. Acta 1308, 81 W7 (1996). 
39. Raymond, C. K. et al. Development of the methylotrophic yeast Pichia methanolica for 
the expression of the 65 kilodalton isoform of human glutamate decarboxylase. Yeast 
14, 11 W23 (1998). 
40. Ellgaard, L. et al. ^ĞƚƚŝŶŐƚŚĞƐƚĂŶĚĂƌĚƐථ PƋƵĂůŝƚǇĐŽŶƚƌŽůŝŶƚŚĞƐĞĐƌĞƚŽƌǇƉĂƚŚǁĂǇ ?286, 
1882 W1888 (2016). 
41. Matsuda, R., Ikeuchi, K., Nomura, S. & Inada, T. Protein quality control systems 
associated with no-go and nonstop mRNA surveillance in yeast. Genes to Cells 19, 1 W
12 (2014). 
42. Payne, T. et al. Modulation of chaperone gene expression in mutagenized 
Saccharomyces cerevisiae strains developed for recombinant human albumin 
production results in increased production of multiple heterologous proteins. Appl. 
Environ. Microbiol. 74, 7759 W66 (2008). 
43. Robinson, A. S., Hines, V. & Wittrup, K. D. Protein disulfide isomerase overexpression 
increases secretion of foreign proteins in Saccharomyces cerevisiae. Biotechnology. 
(N. Y). 12, 381 W384 (1994). 
44. Hayano, T., Hirose, M. & Kikuchi, M. Protein disulfide isomerase mutant lacking its 
isomerase activity accelerates protein folding in the cell. 377, 505 W511 (1995). 
45. Shusta, E. V, Raines, R. T., Pluckthun, A. & Wittrup, K. D. Increasing the secretory 
capacity of Saccharomyces cerevisiae for production of single-chain antibody 
fragments. Nat. Biotechnol. 16, 773 W777 (1998). 
46. Hou, J., Österlund, T., Liu, Z., Petranovic, D. & Nielsen, J. Heat shock response 
improves heterologous protein secretion in Saccharomyces cerevisiae. Appl. 
Microbiol. Biotechnol. 97, 3559 W3568 (2013). 
89 | P a g e  
 
47. Shigechi, H. et al. Direct Production of Ethanol from Raw Corn Starch via Fermentation 
by Use of a Novel Surface-ŶŐŝŶĞĞƌĞĚzĞĂƐƚ^ƚƌĂŝŶŽĚŝƐƉůĂǇŝŶŐ'ůƵĐŽĂŵǇůĂƐĞĂŶĚɲ
Direct Production of Ethanol from Raw Corn Starch via Fermentation by Use of a 
Novel Surface-Engineered Ye. Appl. Environ. Microbiol. 70, 5037 W5040 (2004). 
48. Dragosits, M. et al. The effect of temperature on the proteome of recombinant Pichia 
pastoris. J. Proteome Res. 8, 1380 W1392 (2009). 
49. Curvers, S. et al. Human chymotrypsinogen B production with Pichia pastoris by 
integrated development of fermentation and downstream processing. Part 1. 
Fermentation. Biotechnol. Prog. 17, 495 W502 (2001). 
50. Scheidle, M. et al. High-throughput screening of Hansenula polymorpha clones in the 
batch compared with the controlled-release fed-batch mode on a small scale. FEMS 
Yeast Res. 10, 83 W92 (2010). 
51. Da Silva, N. a. & Srikrishnan, S. Introduction and expression of genes for metabolic 
engineering applications in Saccharomyces cerevisiae. FEMS Yeast Res. 12, 197 W214 
(2012). 
52. Kauffman, K. J., Pridgen, E. M., Doyle, F. J. 3rd, Dhurjati, P. S. & Robinson, A. S. 
Decreased protein expression and intermittent recoveries in BiP levels result from 
cellular stress during heterologous protein expression in Saccharomyces cerevisiae. 
Biotechnol. Prog. 18, 942 W950 (2002). 
53. Karim, A. S., Curran, K. a. & Alper, H. S. Characterization of plasmid burden and copy 
number in Saccharomyces cerevisiae for optimization of metabolic engineering 
applications. FEMS Yeast Res. 13, 107 W116 (2013). 
54. Zhu, T. et al. Efficient generation of multi-copy strains for optimizing secretory 
expression of porcine insulin precursor in yeast Pichia pastoris. J. Appl. Microbiol. 107, 
954 W963 (2009). 
55. Zhu, T., Guo, M., Zhuang, Y., Chu, J. & Zhang, S. Understanding the effect of foreign 
gene dosage on the physiology of Pichia pastoris by transcriptional analysis of key 
genes. Appl. Microbiol. Biotechnol. 89, 1127 W1135 (2011). 
56. Bordes, F., Fudalej, F., Dossat, V., Nicaud, J.-M. & Marty, A. A new recombinant 
protein expression system for high-throughput screening in the yeast Yarrowia 
lipolytica. J. Microbiol. Methods 70, 493 W502 (2007). 
57. Huang, M. et al. Microfluidic screening and whole-genome sequencing identifies 
mutations associated with improved protein secretion by yeast. Proc. Natl. Acad. Sci. 
U. S. A. 112, E4689-96 (2015). 
58. Academy, C., Umr, C. & Nice, M. Surprisingly diverged populations of Saccharomyces 
cerevisiae in natural environments remote from human activity. 5404 W5417 (2012). 
doi:10.1111/j.1365-294X.2012.05732.x 
59. Bussey, H. K1 killer toxin, a pore-forming protein from yeast. Mol. Microbiol. 5, 2339 W
2343 (1991). 
60. Bostian, K. A. et al. Sequence of the preprotoxin dsRNA gene of type I killer yeast: 
90 | P a g e  
 
multiple processing events produce a two-component toxin. Cell 36, 741 W751 (1984). 
61. Zhu, H. & Bussey, H. Mutational analysis of the functional domains of yeast K1 killer 
toxin. Microbiology 11, 175 W181 (1991). 
62. Schmitt, M. J. & Breinig, F. Yeast viral killer toxins: lethality and self-protection. Nat. 
Rev. Microbiol. 4, 212 W21 (2006). 
63. Schmitt, M. J. & Reiter, J. Viral induced yeast apoptosis. Biochim. Biophys. Acta - Mol. 
Cell Res. 1783, 1413 W1417 (2008). 
64. Toh, E. A. & Wickner, R. B. A mutant killer plasmid whose replication depends on a 
ĐŚƌŽŵŽƐŽŵĂů ‘ƐƵƉĞƌŬŝůůĞƌ ?ŵƵƚĂƚŝŽŶ ?Genetics 91, 673 W682 (1979). 
65. Sherman, B. F., Sherman, M. F. & Enzymol, M. Getting started with yeast. Methods 
Enzymol. 41, 3 W41 (2003). 
66. Inoue, H., Nojima, H. & 0kayama, H. High efficiency transformation of Escherichia coli 
with plasmids. 96, 23 W28 (1990). 
67. Untergasser, A. et al. Primer3 - new capabilities and interfaces. Nucleic Acids Res. 40, 
e115 (2012). 
68. Labun, K., MonƚĂŐƵĞ ?d ?' ? ?'ĂŐŶŽŶ ?: ? ? ?dŚǇŵĞ ?^ ? ? ?sĂůĞŶ ? ?,KW,KW ǀ ථ PĂ
web tool for the next generation of CRISPR genome engineering. 1 W5 (2016). 
doi:10.1093/nar/gkw398 
69. Brodersen, D. E. et al. The structural basis for the action of the antibiotics tetracycline, 
pactamycin, and hygromycin B, on the 30S ribosomal subunit. Cell 103, 1143 W1154 
(2000). 
70. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. ImageJ, https://imagej.nih.gov. 
(1997). 
71. Flagfeldt, D. B., Siewers, V., Huang, L. & Nielsen, J. Characterization of chromosomal 
integration sites for heterologous gene expression in Saccharomyces cerevisiae. Yeast 
26, 545 W551 (2009). 
72. E.J.Louis. E.J.Louis, Personal communication to M.F.Tuite. 
73. Madden, T. L., Tatusov, R. L. & Zhang, J. Computer methods for macromolecular 
sequence analysis. Methods in Enzymology 266, (Elsevier, 1996). 
74. Cherry, J. M. et al. Saccharomyces Genome Database: The genomics resource of 
budding yeast. Nucleic Acids Res. 40, 700 W705 (2012). 
75. ƌƌŽǇŽ ?: ? ?&ĂƌŬĂƓ ?s ? ?^ĂŶǌ ?. B. & Cabib, E. Strengthening the fungal cell wall through 
chitin-glucan cross-links: effects on morphogenesis and cell integrity. Cell. Microbiol. 
(2016). doi:10.1111/cmi.12615 
76. Kawai, S., Hashimoto, W. & Murata, K. Transformation of Saccharomyces cerevisiae 
and other fungi: methods and possible underlying mechanism. Bioeng. Bugs 1, 395 W
403 (2010). 
77. Ito, H., Fukuda, Y., Murata, K. & Kimura, A. Transformation of intact yeast cells treated 
91 | P a g e  
 
with alkali cations. J. Bacteriol. 153, 163 W168 (1983). 
78. Chen, P. et al. Visualized investigation of yeast transformation induced with Li+ and 
polyethylene glycol. Talanta 77, 262 W268 (2008). 
79. Xie, X. & Lipke, P. N. On the evolution of fungal and yeast cell walls. 48, 1 W6 (2010). 
80. Zhang, L. et al. Large genomic fragment deletions and insertions in mouse using 
CRISPR/Cas9. PLoS One 10, 1 W14 (2015). 
81. Iuliana V. Ene, Louise A. Walker, Marion Schiavone, Keunsook K. Lee, Hélène Martin-
Yken, B Etienne Dague, Neil A. R. Gow, Carol A. Munro, A. J. P. B. Complex 
haploinsufficiency-based genetic analysis of the NDR/Lats kinase Cbk1 provides insight 
into its multiple functions in C. albicans. Genetics 6, 1 W15 (2016). 
82. Nakayashiki, T., Kurtzman, C. P., Edskes, H. K. & Wickner, R. B. Yeast prions [ URE3 ] 
and [ PSI ] are diseases. 102, 10575 W10580 (2005). 
83. Philliskirk, G. & Young, T. W. The occurrence of killer character in yeasts of various 
genera. Antonie Van Leeuwenhoek 41, 147 W151 (1975). 
84. Wickner, R. B. & Edskes, H. K. Yeast killer elements hold their hosts hostage. PLOS 
Genet. 11, e1005139 (2015). 
85. Allen, S. a et al. Furfural induces reactive oxygen species accumulation and cellular 
damage in Saccharomyces cerevisiae. Biotechnol. Biofuels 3, 2 (2010). 
86. Cabiscol, E., Piulats, E., Echave, P., Herrero, E. & Ros, J. Oxidative stress promotes 
specific protein damage in Saccharomyces cerevisiae. J. Biol. Chem. 275, 27393 W27398 
(2000). 
87. Herker, E. et al. Chronological aging leads to apoptosis in yeast. J. Cell Biol. 164, 501 W
507 (2004). 
88. Marquina, D., Santos, A. & Peinado, J. Biology of killer yeasts. Int. Microbiol. 5, 65 W71 
(2002). 
89. Matai, L. et al. Oxidative homeostasis regulates the response to reductive 
endoplasmic reticulum stress through translation control. CellReports 1 W15 (2016). 
doi:10.1016/j.celrep.2016.06.025 
90. Paschen, W., Mengesdorf, T., Althausen, S. & Hotop, S. Peroxidative stress selectively 
down-regulates the neuronal stress response activated under conditions of 
endoplasmic reticulum dysfunction. J. Neurochem. 76, 1916 W1924 (2001). 
91. Cala, S. E. GRP94 hyperglycosylation and phosphorylation in Sf21 cells. Biochim. 
Biophys. Acta - Mol. Cell Res. 1496, 296 W310 (2000). 
92. Dey, A., Kessova, I. G. & Cederbaum, A. I. Decreased protein and mRNA expression of 
{ER} stress proteins {GRP78} and {GRP94} in HepG2 cells over-expressing {CYP2E1}. 
Arch. Biochem. Biophys. 447, 155 W166 (2006). 
93. Yandell, J. K. & Yonetani, T. Steady-state kinetics of yeast cytochrome c peroxidase 
catalyzed oxidation of inorganic reductants by hydrogen peroxide. Biochim. Biophys. 
92 | P a g e  
 
Acta - Protein Struct. Mol. Enzymol. 748, 263 W270 (1983). 
94. Zito, E., Chin, K. T., Blais, J., Harding, H. P. & Ron, D. ERO1-beta, a pancreas-specific 
disulfide oxidase, promotes insulin biogenesis and glucose homeostasis. J. Cell Biol. 
188, 821 W832 (2010). 
95. Konno, T. et al. ERO1-independent production of H2O2 within the endoplasmic 
reticulum fuels Prdx4-mediated oxidative protein folding. J. Cell Biol. 211, 253 W9 
(2015). 
96. Bulleid, N. J. & Ellgaard, L. Multiple ways to make disulfides. Trends Biochem. Sci. 36, 
485 W492 (2016). 
97. Dai, Q., Sun, Z. & Schnabel, G. Development of spontaneous hygromycin B resistance 
in Monilinia fructicola and Its impact on growth rate, morphology, susceptibility to 
demethylation Inhibitor fungicides, and sporulation. Phytopathology 93, 1354 W1359 
(2003). 
98. Perez, F. Serial Cloner. (2013). 
 
